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ABSTRACT 
 The mechanism of biomineralization is unknown. In bone, it has been proposed that 
an acidic phosphoprotein of the extracellular matrix (ECM) is important in the nucleation of 
hydroxyapatite (HA). The mineralized tissue protein, bone sialoprotein (BSP), has been 
shown to be a potent nucleator of HA and this activity is increased upon binding to type I 
collagen. The collagen-binding domain of BSP has been determined to be a highly conserved 
region (spanning amino acid residues 18-45); however, the area of collagen involved in this 
interaction is unknown.   
 In this study, a chemical cross-linking method was initially utilized to map the BSP-
binding region on collagen. These experiments involved the incubation and interaction of 
five different single-cysteine recombinant BSP (1-100) mutants and type I collagen in the 
presence of two sulfhydryl-reactive, photoactivatable cross-linking reagents: ρ-azidophenacyl 
bromide (APB) and N-[4-(ρ-azidosalicylamido) butyl]-3’-(2’-pyridyldithio) propionamide 
(APDP).  However, due to the low yield observed from SDS-PAGE in all instances, the 
complexes were not further characterized.  
 As an alternate approach, rotary-shadowing transmission electron microscopy (TEM) 
was used. This involved incubation of recombinant BSP (rBSP) with type I collagen, rotary-
shadowing with platinum and analysis by TEM. Rotary-shadowing of BSP revealed a 10-nm 
globular structure that is linked to a thread-like structure of ~25 nm while type I collagen 
appeared as semi-flexible, rod-like structures. Combining BSP and collagen showed a locus 
of interaction at a site that averages approximately 31% from the N-terminus, based on the 
site of interaction of an antibody to the N-terminus of the collagen molecule. Due to the 
observed variability, BSP interacts with collagen between residues 255-375.  Based on the 
locus of interaction, the arrangement of the collagen fibril, the highly flexible structure of 
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BSP and the hydrophobic nature of the BSP-collagen binding interaction, we postulate that 
the N-terminal hydrophobic sequence (residues 18-45) of BSP binds collagen in an overlap 
region at a site that is rich in hydrophobic residues, while the two glutamic acid-rich regions 
extend into the gap region of the adjacent collagen molecule. 
 Within the collagen-binding domain of BSP, there is a highly conserved thrombin-
cleavage site at Arg27-Tyr28. Thrombin cleaves rat BSP in the middle of the collagen-
binding domain (residues 18-45), which effectively abolishes collagen-binding, implying 
physiological significance. To address the relevance, incubation of thrombin with BSP and 
fibrillar collagen and with demineralized bone chips was performed to determine if BSP was 
released from its complexes. Analysis with SDS-PAGE and western blotting demonstrated 
that rBSP bound to type I collagen fibrils is susceptible to thrombin cleavage. Similarly, 
endogenous BSP present in demineralized bone chips is also released from these chips with 
thrombin incubation. Since BSP appears to enhance osteoprogenitor cell migration and 
differentiation, this suggests that, upon injury, the release of BSP from bone may provide 
signals to initiate the repair process. In summary, the results from these studies are important 
in better understanding the BSP-collagen interaction and its role in bone formation and 
mineralization. 
 
Keywords bone sialoprotein, phosphoprotein, SIBLING proteins, type I collagen, 
biomineralization, hydroxyapatite nucleation, chemical cross-linking, electron microscopy, 
protein-collagen interaction, thrombin 
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1.1 GENERAL INTRODUCTION   
 Bone is a specialized connective tissue consisting of three main components: 
mineral, cells and extracellular matrix (ECM). Bone undergoes constant change through 
remodeling,a process involving the resorption of bone and its reformation. Bone has three 
primary functions: (1) mechanical support, (2) protection of vital organs, and (3) storage 
of calcium and phosphate ions as a reserve which are essential for homeostasis (1, 2). 
Within bone, there are three phases: a cellular, organic and inorganic phase.  
 The cellular phase consists of three different bone cells: osteoblasts, osteoclasts 
and osteocytes (3). The organic phase comprises predominantly type I collagen (90%) 
and non-collagenous proteins (NCPs) such as osteopontin (OPN) and bone sialoprotein 
(BSP). The inorganic phase comprises 65% of the total bone weight and is composed 
primarily of hydroxyapatite crystals [HA; Ca10(PO4)6(OH)2] which contribute to the 
mechanical rigidity of bone.  
 Biomineralization is a complex, yet poorly characterized process that involves 
many factors.  Precise mechanisms of initiation, growth and packing of crystals are 
unknown. Several mechanisms for biomineralization have been postulated, including the 
proposal that an acidic phosphoprotein present in the ECM of mineralized tissues, when 
bound to type I collagen, will induce the nucleation of HA (4). BSP is an acidic non-
collagenous phosphoprotein that is expressed primarily in mineralized tissues (5) and has 
been shown to be a potent nucleator of HA (6, 7). It is postulated that BSP is secreted into 
the ECM by osteoblasts, binds to type I collagen in the gap regions or the regions 
adjacent to it, and mediates mineral formation (Figure 1.1). 
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Figure 1.1 Model of BSP-mediated hydroxyapatite nucleation.   
(A) The hydroxyapatite crystals (HA) are deposited onto a type I collagen-rich matrix. 
The collagen matrix neither promotes nor inhibits HA nucleation, but rather acts as the 
scaffold upon which HA crystals are deposited. BSP is a potent nucleator of HA with the 
two glutamic acid-rich regions (brown) being responsible for the activity and this 
nucleation activity is increased 10-fold when bound to type I collagen. Furthermore, BSP 
is postulated to bind to type I collagen (purple) in the gap regions or regions adjacent to it 
where early mineral formation is seen to occur. (B) Electron micrograph of calcified 
turkey tendon showing initial mineral formation occurring in the gap regions of collagen. 
[Adapted from (8)]  
A 
B 
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1.2 BONE DEVELOPMENT 
 The bones of the modern human skeleton are formed by two different processes: 
endochondral ossification and intramembranous ossification (9, 10). Long bones of the 
body are formed through endochondral ossification while the flat bones form through 
intramembranous ossification. Both processes involve condensation of mesenchymal 
stem cells (MSCs), differentiation of these cells, secretion of an osteoid (uncalcified bone 
matrix) and the initial formation of woven bone that is eventually remodeled to mature 
lamellar bone. The main difference between the two bone development processes is the 
presence of a cartilaginous intermediate in endochondral ossification (9).  
1.2.1 Skeletal Cell Types 
1.2.1.1 Osteoblasts 
 Osteoblasts are derived from MSCs, more specifically, the osteoprogenitor cells 
within the periosteum and bone marrow. Differentiation into osteoblasts is induced by 
various growth factors such as bone morphogenetic proteins (BMPs) and once 
differentiated; these cells display a range of genetic markers including Osterix, alkaline 
phosphatase and BSP. Osteoblasts are responsible for synthesizing the osteoid matrix via 
the secretion of collagenous and non-collagenous proteins (10).  
1.2.1.2 Osteocytes  
  Osteocytes are the most abundant cells in bone tissue, comprising over 90% (11, 
12). These cells are derived from mature osteoblasts that become engulfed in the 
mineralized tissue. Osteocytes are interconnected by long cytoplasmic extensions known 
as canaliculi and reside in spaces called lacunae (11, 13). These canaliculi function as 
routes for nutrients and oxygen transport and exchange. Additionally, osteocytes are 
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thought to act as mechanosenors such as for strain/stress and detecting fractures within 
the bone, and are crucial to the bone-remodeling process. 
1.2.1.2 Osteoclasts 
 Osteoclast precursors are haematopoietic in origin, arising from the spleen and 
bone marrow. Osteoclast precursors are derived from the monocyte/macrophage lineage. 
Osteoclasts are multinuclear (containing 10-20 nuclei with 1-2 nucleoli in each nucleus), 
and are responsible for bone remodeling in the process known as bone resorption (12). 
1.2.2 Intramembranous Ossification 
 Intramembranous ossification is the process for formation of flat bones, which 
include the skull and mandible. A cartilaginous intermediate is not present in this process. 
MSCs condense within a highly vascularized area of embryonic tissue and differentiate 
directly into pre-osteoblasts and eventually osteoblasts in regions known as ossification 
centres. Osteoblasts begin to secrete an osteoid matrix rich in type I collagen. 
Calcification traps many of the osteoblasts in the mineralized tissue where they 
differentiate into osteocytes. Osteoblasts and osteocytes deposit non-collagenous proteins 
and type I collagen aggregate randomly to form woven bone. Most of the woven bone is 
eventually remodeled and replaced by mature lamellar bone by clustering type I collagen 
fibrils in parallel arrays (9).   
1.2.3 Endochondral Ossification 
 Endochondral ossification is a multi-step process requiring the formation and 
degradation of a cartilaginous intermediate that serves as template for the formation of 
long bones in the human body (9). MSCs condense, proliferate and differentiate into 
chondrocytes all while depositing a cartilaginous ECM comprising of mainly type II 
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collagen and cartilage-specific matrix proteins and proteoglycans. The tissue grows 
axially following the growth plates present at each end of the forming tissue. This process 
continues until the growth plates close at puberty.  
 In the process of mineralization, chondrocytes mature into hypertrophic 
chondrocytes and undergo apoptosis. The hypertrophic chondrocytes express proteins 
distinctly different from those expressed by chondrocytes, including collagen type X, 
BSP, matrix Gla protein and OPN (14). Following this event, vascular invasion allows 
the recruitment of osteoclast precursors from the circulation which then proceed to resorb 
the calcified cartilaginous matrix and induce the remodeling of the tissue mediated by 
osteoblasts. Osteoblasts synthesize osteoid via secretion of both collagenous and non-
collagenous proteins. Following calcification, woven bone is initially formed and is 
eventually remodeled and replaced with mature lamellar bone.  
1.2.4 Bone Repair 
 Bone repair occurs through a sequence of four stages: inflammation, soft callus 
formation, hard callus formation and remodeling. In response to bone injury, the blood 
coagulation cascade is activated to form a haematoma. Over two to three days, the 
haematoma is gradually replaced by granulation tissue. Progenitor cells of the periosteum 
(membrane of connective tissue that lies the outer surface of bone) nearest the fracture 
site differentiate into chondrocytes and synthesize cartilage, while progenitor cells further 
away differentiate into osteoblasts and synthesize osteoid. Together, these processes form 
the soft callus. Following calcification of the osteoid, a hard callus of woven bone is 
formed, while the cartilage becomes hyaline cartilage. Eventually, a union of the fracture 
gap occurs and the woven bone is remodeled by osteoclasts and osteoblasts to eventually 
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form mature lamellar bone (15). Bone remodeling will continue until the form and 
strength of the bone are restored to conditions prior to the fractured state.  
 If the injury is too severe that natural healing cannot repair the bone fracture, then 
surgical procedures may help in the healing process. For example, metal scaffolds 
(primarily titanium) are often used to hold the fractured bones in place to facilitate the 
bone healing. Additionally, the metal scaffolds may be coated with components that have 
been shown to increase bone repair such as HA, type I collagen, BSP or BMP (16). 
1.3 BIOMINERALIZATION 
 Biomineralization refers to the process by which organisms use dissolved ions to 
form mineral crystals (17). Biological organisms have been using minerals for over 3.5 
billion years and the earliest evidence of this process is the fossil of stromatolites 
entrapped in sedimentary rocks. Mineralized skeletal structures first appeared 
approximately 540 million years ago (18) and are either comprised of calcium carbonate 
or calcium phosphate. Calcium carbonate-based skeletal systems are found primarily in 
invertebrates such as molluscs and crustacean, whereas a crystalline form of calcium 
phosphate in the form of HA, is found in bones and teeth. 
  By transmission electron microscopy (TEM), HA crystals found in bone, dentin 
and mineralized tendon tend to be plate-like, with average dimensions of ~45 nm in 
length, ~25 nm in width and 3-6 nm thick (3, 19). Moreover, the c axes of the HA 
crystals are aligned with the collagen fibril axis (20).  
 Today, biomineralization occurs in all five biological kingdoms resulting in 
diverse array of minerals for skeletal, taxis and protective functions (17). 
Biomineralization still remains an active area of research as precise mechanisms of 
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initiation, growth and packing of crystals are unknown. However, it is believed that this 
process is tightly regulated by secreted proteins in the human body, as spontaneous 
calcifications are rare in healthy individuals. While there are several postulated 
mechanisms for biomineralization, including the involvement of matrix vesicles (21, 22) 
and inhibition mechanisms involving the removal of mineralization inhibitors (23-26), 
one mechanism to account for bone mineralization that has significant support in the 
literature is discussed below. 
1.3.1 Organic Matrix-Mediated Mineralization 
 Organic matrix-mediated biomineralization involves the presence of a surface that 
promotes nucleation of crystals (27). The surface chemistry of the organic matrix is 
imperative to crystal formation and growth. In regards to the proteins found in the 
organic matrix, the surface chemistry is dictated by the primary and secondary structure 
and/or post-translational modifications (PTMs) (28). To date, proteins identified to be 
mediators of crystal formation and growth are highly acidic and phosphorylated (29). 
  In organic matrix-mediated biomineralization, there are four steps involved in 
crystal formation. The first two steps involve the sequestration and adsorption of Ca
2+
 
and PO4
3- 
ions onto an organic matrix leading to the nucleation and formation of 
nanometer-sized particles and eventually critical nuclei. The two following steps involve 
the stabilization of the critical nuclei and as a result, the formation of HA crystals (27).  
 In bone, it is proposed by some that mineralization occurs through a process 
known as epitactic nucleation where a protein mimics a crystal face resulting in the 
formation of a critical nucleus (17). More specifically, the proposed mechanism involves 
type I collagen acting as the pre-existing surface upon which the ions are deposited and 
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nucleated by acidic proteins (4, 30-32). BSP is an acidic non-collagenous phosphoprotein 
that is expressed primarily in mineralized tissues (5) and has been shown to be a potent 
nucleator of HA (6, 7, 33). BSP will be discussed in greater detail later in this chapter.  
1.4 ORGANIC PHASE 
 The organic phase of bone comprises 30% of the total bone weight and is 
deposited primarily by osteoblasts and to a lesser extent, osteocytes. It is composed 
predominantly of type I collagen (90%) and NCPs such as OPN and BSP. Type I 
collagen neither promotes nor inhibits HA nucleation, but merely acts as a structural 
scaffold upon which HA are deposited.  However the NCPs, specifically the SIBLING 
proteins (discussed later in this section), are proposed to be important in bone 
mineralization. 
1.4.1 Type I Collagen  
 There are more than 29 types of collagen, with type I collagen being the most 
abundant in the human body. Dividing into subgroups based on the polymeric structures 
assembled, type I collagen belongs to the fibril-forming collagen superfamily, which 
includes type II, III, V and XI collagen. Type I collagen is a cationic molecule with an 
isoelectric point of 8.3. Type I collagen is found in bone, dentin, skin, tendon, ligaments 
and cornea and its expression is primarily restricted to cells that form these tissues 
including osteoblasts and fibroblasts (34).  
1.4.1.1 Type I Collagen Structure 
 Type I collagen is comprised of three left-handed polypeptides – two identical α1 
chains and one α2 chain. Each polypeptide comprises approximately 1,000 amino acid 
residues and is approximately 100 kDa (34, 36, 37). The three polypeptides wind together 
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to form a right-handed triple-helical structure with short non-helical telopeptides at both 
ends (Figure 1.2A) (37, 38). Therefore, the molecular weight of the full, triple-helical 
collagen structure is approximately 300 kDa.  
 Type I collagen has a characteristic repeating Gly-X-Y sequence, where X is 
commonly proline and Y is commonly 4-hydroxyproline. These residues are important in 
limiting the rotation of the polypeptide chains (34, 35). The 4-hydroxyproline residue is 
also involved in the stabilization of the triple-helix by forming hydrogen bonds and water 
bridges (34). The glycine residue at every third amino acid along each chain is crucial for 
the formation of the helix turn, since glycine has the smallest side chain and can fit within 
the centre of the triple helix, whereas the side chains of all the other amino acids cannot 
without disrupting the triple helix (35).   
1.4.1.2 Type I Collagen Fibril Formation  
 Type I collagen monomers, which are approximately 300 nm in length and 1.4 nm 
in diameter, spontaneously aggregate forming fibrils resulting in overlap and gap regions 
with a periodicity (D) of 67 nm or 234 residues (Figures 1.2A and 1.2B) (37, 39). This 
arrangement is referred to as a staggered array or the Hodge and Petruska model (40). 
Each overlap region is approximately 27 nm (0.4 D) while each gap region is 
approximately 40 nm (0.6 D). In addition, the pore space between adjacent type I 
collagen molecules is 0.24 nm. The characteristic banding pattern resulting from the 
overlap and gap regions can be observed by negative staining of the collagen fibrils 
(Figure 1.2C) (37, 39). Moreover, positive staining of type I collagen fibrils with 
phosphotungstic acid (PTA) results in twelve bands within a D-period that are designated 
as a1-a4, b1, b2, c1-c3, d, and e1 and e2 (Figures 1.2D and 1.2E). These bands are a result of 
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the uptake of PTA anions by positively charged amino acids (i.e. lysine, hydroxylysine, 
arginine, and to a lesser extent, histidine) (41, 42). The gap region of the collagen fibril 
consists of a3,2,1, e2,1, d and c3 while the overlap region consists of c2,1, b2,1, and a4,3.   
 Side-to-side intermolecular interactions, rather than end-to-end interactions, are 
important in maintaining the integrity of the collagen fibril (39). In addition, the non-
helical telopeptides are important for stabilizing the collagen fibrils by facilitating 
intermolecular cross-links (39). Interestingly, early mineral formation has been observed 
in the gap regions of collagen fibrils. 
 There are many proposed models of the 3-D organization of type I collagen, 
however; there is one model that has significant support in the literature. Landis et al., 
proposed that the packing of consecutive 2-D collagen arrays into 3-D assemblages 
results in the formation of channels or gaps. These channels or gaps (with pore sizes of 
0.24 nm) are postulated to be the sites of nucleation (43).  
 Although the structure of type I collagen is quite complex, the structure is 
physiologically relevant. To date, approximately 200 mutations have been characterized 
in the two genes, COL1A1, COL1A2, encoding the 2 different α chains of type I 
collagen. These mutations result in severe pathological conditions such as osteogenesis 
imperfecta (OI) and Ehlers-Danlos syndrome (44).  
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Figure 1.2 Type I collagen structure.  
 (A) Triple-helical type I collagen monomers spontaneously aggregate forming fibrils 
which result in (B) overlap and gap regions with a D-periodicity of 67 nm. (C) The 
characteristic banding pattern resulting from the overlap and gap regions are observed by 
negative staining with sodium phosphotungstic acid (1 %, pH 7). (D) The collagen fibrils 
were positively stained with phosphotungstic acid (1 %, pH 3.4) and then uranyl acetate 
(1 %, pH 4.2) resulting in (E) twelve staining bands. [Adapted from (45)] 
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1.4.1.3 Biosynthesis of Type I Collagen  
 The fibril-forming collagen family is first synthesized in the endoplasmic 
reticulum (ER) as soluble procollagen. They are then converted into collagen molecules 
via a series of enzymatic reactions. Proline residues at the Y position of the Gly-X-Y 
repeat and lysine residues undergo hydroxylation to 4-hydroxyproline and hydroxylysine 
by prolyl-4-hydroxylase and lysyl hydroxyalase (46). Some of the proline residues at the 
X position are converted to 3-hydroxyproline by prolyl-3-hydroxylase. In terms of the 
hydroxylysine residues, galactose or both galactose and glucose are added to selected 
residues. Once the C-terminal propeptides associate and form intrachain and interchain 
disulfide bonds, the triple-helical conformation starts to assemble and propagate toward 
the N-terminus in a zipper-like manner.  
 Following or during secretion into the ECM, cleavage of N - and C- propeptides 
by procollagen N- and C- proteinases allows for the self-assembly of collagen monomers 
into collagen fibrils (37, 47). Furthermore, to stabilize the collagen fibrils, the enzyme 
lysyl oxidase converts selected lysine and hydroxylysine residues (found in the non-
helical telopeptides) to aldehyde derivatives leading to cross-link formation.  
1.4.2 The SIBLING Protein Family  
 The ECM contains many non-collagenous proteins including the SIBLING (Small 
Integrin-Binding LIgand, N-linked Glycoprotein) protein family (48, 49). Members of the 
SIBLING protein family include: OPN, dentin matrix protein 1 (DMP-1), dentin 
sialophosphoprotein [DSPP – under physiological conditions, DSPP is cleaved by PHEX 
forming dentin sialoprotein (DSP) and dentin phosphophoryn (DPP)], matrix 
extracellular phosphoglycoprotein (MEPE) and bone sialoprotein (BSP) (48, 50).  
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 The SIBLING proteins are expressed predominantly in mineralized tissues and 
are proposed to have important roles in mineralization. In bone and dentin, BSP and OPN 
exist as full-length forms, whereas DMP-1 and DSPP exist as distinct proteolytic-derived 
large peptides. The SIBLING proteins share many features such as gene location and 
structural characteristics (48, 50). The genes encoding the SIBLING proteins are all 
located within a 375,000 bp region on chromosome 4q21 (human) and display similar 
exon structures (50). It is likely that the SIBLING genes arose by gene duplication and 
divergence (49). Structural characteristics shared among the SIBLING proteins include 
the presence of an Arg-Gly-Asp (RGD) site which is important in cell-integrin binding, 
PTMs such as phosphorylation and glycosylation and high levels of acidic amino acids 
(51).   
1.4.2.1 SIBLING Structure  
 Members of the SIBLING family possess a loose, flexible structure and this lack 
of structure has been postulated to be important for interacting with numerous binding 
partners including collagen, integrins and HA (49). NMR studies of OPN (49) and DPP 
(52) reveal the proteins to adopt a random coil conformation. Based on secondary-
structure prediction programs, circular dichroism (CD) (53) and small-angle X-ray 
scattering (54), DMP-1 has also been shown to possess a random coil secondary 
structure. Of relevance, secondary structure programs predict MEPE to be an 
unstructured protein (55). Finally, BSP has been shown to be unstructured as will be 
discussed in greater detail later in this chapter. 
1.4.2.2 Post-Translational Modifications of SIBLING Proteins  
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 The SIBLING proteins are heavily modified by PTMs such as glycosylations and 
phosphorylations. Phosphorylations occur on serine, threonine and to a lesser extent, 
tyrosine residues. The kinases postulated to be responsible for phosphorylation are Golgi 
casein kinase (gCK), protein kinases (CK1 and CK2) and FAM20 (56). MS analysis of 
rat bone-extracted OPN show an average of 10 phosphate groups per molecule (57). DSP 
has between 6 to 10 phosphate groups (58) while DPP (comprising approximately 450 
amino acid residues) is heavily phosphorylated with an average of 209 phosphates (59). 
The SIBLING protein DMP-1 exists as 37-kDa and 57-kDa peptides based on relative 
mobility on SDS-PAGE, containing 12 and 41 phosphates, respectively (60). 
Phosphorylation has been demonstrated to have a significant impact on the SIBLING 
proteins’ ability to modulate mineral formation. For example, phosphorylation of OPN is 
required for HA inhibition (57) while the phosphorylation of the 57 kDa fragment of 
DMP-1 alters its function from being a HA inhibitor to a HA nucleator (60). In dentin, 
Torres-Quintana et al. found that mineralization was decreased in the presence of kinase 
inhibitors, demonstrating the importance of these phosphorylations (61).  
 The SIBLING proteins also contain variable levels of glycosylation (e.g., rat 
bone-extracted OPN has four O-linked oligosaccharides); however, their precise 
functions are unknown. 
1.4.2.3 SIBLING Function  
 The SIBLING proteins BSP, DMP-1 and DPP are thought to be HA nucleators 
whereas OPN and MEPE are thought to be inhibitors of HA. These proteins are 
expressed predominantly in mineralized tissues and are proposed to be important in 
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mineralization. Knock-out models of the various SIBLING proteins have been generated 
and all display abnormalities in bone and/or tooth formation.  
 At the early stages in life, there are observable bone phenotypes in BSP-deficient 
mice. At 0-4 months, the mice show decreased mineralization of cortical bones and 
shortened long bones, suggesting BSP is important in early mineral formation. DSPP-null 
mice displayed extensive tooth abnormalities similar to dentinogenesis imperfecta type 
III, a condition characterized by enlarged pulp chambers, increased width of predentin 
zone, hypomineralization and pulp exposure (62). Skeletal abnormalities such as enlarged 
growth plates, as well as dentin wall hypomineralization, are evident in DMP-1 knock-
out mice (63, 64). Increased mineral content and bone mass are present in OPN-deficient 
and MEPE-deficient mice. Collectively, these findings demonstrate the physiological 
importance of the SIBLING proteins for proper bone and tooth formation (23, 65).  
1.4.3 Bone Sialoprotein 
 Bone sialoprotein (BSP) is an acidic non-collagenous phosphoprotein and a 
member of the SIBLING protein family. This acidic protein was first isolated as 25 kDa 
fragments from the cortical bone of cow by Herring in 1963 (66). However, due to 
difficulties in extracting the protein, it was not until 1983 that intact BSP was purified 
from fetal calf bone by Fisher et al., (67). BSP has also been isolated from pig (68), rat 
(69), human (70), rabbit (71) and chicken (72) (Figure 1.3). More recently, a BSP-like 
protein has been identified in amphibian (African clawed toad) and reptile (caiman) 
species (73).  
 Mammalian BSP contains approximately 327 amino acid residues, 16 of which 
are the signal peptide (Figure 1.3). BSP contains the following functional domains: a 
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hydrophobic region near the N-terminus (spanning residues 18-45) shown to bind to type 
I collagen (74) two glutamic acid-rich regions located in the middle of the molecule, 
which are responsible for HA binding and nucleation and a C-terminal RGD cell-binding 
motif (75). Of relevance, there is a highly conserved thrombin-cleavage site at Arg27-
Tyr28 within the type I collagen binding region (unpublished data). 
 Analysis of the deduced amino acid sequences of BSP from different mammalian 
species shows a high level of conservation. Moreover, identity of up to 90% is observed 
within specific domains (i.e., the two glutamic acid-rich regions, the RGD motif and the 
collagen-binding domain) (74, 76). The high level of conservation of these domains 
among species implies preservation of function (Figure 1.4).  
1.4.3.1 Secondary Structure of Bone Sialoprotein 
 BSP has been shown by NMR (49, 77), CD spectroscopy (6, 78) and small angle 
X-ray scattering (6) to possess a loose, flexible structure. Furthermore, after rotary-
shadowing TEM, BSP appears as a monomer possessing a ~10 nm globular structure 
linked to an elongated thread-like structure (~25 nm) (78). Similar to other SIBLING 
proteins, it has been hypothesized that this lack of order allows BSP to simultaneously 
interact with proteins such as type I collagen (49). 
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Figure 1.3. Schematic of BSP functional domains.  
 BSP contains the following functional domains: type I collagen-binding region (residues 
18-45), two glutamic acid-rich regions (which are important for HA binding and 
nucleation) and a RGD cell-binding motif. Within the type I collagen binding region, 
there is a thrombin cleavage site at Arg27-Tyr28 (insert). Post-translational modifications 
such as N- and O- linked glycosylations, phosphorylations and tyrosine sulfations are 
shown. 
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Figure 1.4 Sequence alignments for mammalian bone sialoprotein.  
The amino-acid sequences were aligned to generate a consensus sequence. Residues that 
are identical in five of the six sequences are indicated by upper case letters in the 
consensus sequence, whereas residues identical in three or more sequences are indicated 
by lower case letters. Residues that are conserved in fewer than three sequences are 
indicated by a period. [Adapted from (76)]   
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1.4.3.2 Post-Translational Modifications of Bone Sialoprotein  
 BSP is heavily modified by PTMs which account for up to 30% of the molecular 
weight of native BSP. PTMs include N- and O- linked glycosylations, phosphorylations, 
tyrosine sulfations and transglutaminase cross-linking. In the absence of PTMs, BSP has 
a molecular weight of approximately 33-34 kDa (calculated from the amino acid 
sequence). However, as a result of the heterogeneity in PTMs that BSP undergoes, the 
molecular weight of individual BSP molecules is highly variable. Based on two separate 
MS studies of human bone-derived BSP, the mean mass was determined to be ~52.5 kDa 
(79) and ~49 kDa (80). In both studies, a broad peak width (~20 kDa) was observed in 
the mass spectrum, reflecting the heterogeneity in PTMs. Of relevance, based on SDS-
PAGE, native BSP has an apparent molecular weight of 60-80 kDa.  
 To date, two sulfated tyrosine residues near the RGD sequence (Tyr 259 or 263 
and Tyr 297 or 298) have been identified (79). Although it was initially hypothesized that 
these residues may modulate cell-attachment capabilities, Midura et al., found that both 
bone-extracted and rBSP (unmodified BSP) have comparable cell attachment capabilities 
(81). Moreover, blocking of sulfation with chlorate treatment did not alter cell attachment 
capabilities of bone-extracted BSP.   
 The mammalian BSP sequence has three putative sites for N-linked glycosylation 
(Asn-X-Ser/Thr) located in the middle of the protein, two of which are conserved across 
all mammalian species (82). In addition, there is a fourth putative site for N-linked 
glycosylation in human BSP near the N-terminus (83). Matrix-assisted laser desorption 
mass spectrometry (MALDI-TOF MS) analysis of human bone-derived BSP has revealed 
2 N-linked oligosaccharides (Asn 161 and Asn 166) and 11 O-linked oligosaccharides 
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(Ser 92, 214 and 232 and Thr 95, 165, 167, 213, 214, 223, 230, 231 and 232) (84). In 
human bone-extracted BSP, Wutkke et al., identified only 8 of the 11 O-linked 
oligosaccharides and 4 N-linked oligosaccharides. Collectively, these studies demonstrate 
that glycosylation tends to be heterogeneous in both the level and sites of modification. 
Although the role of these glycosylations on BSP remains unclear, these modifications 
have no apparent affect on collagen-binding activity (74). 
 Similar to other SIBLING proteins, BSP is highly phosphorylated, particularly at 
serine and threonine residues. The mammalian BSP sequence has 5 putative serine 
phosphorylation sites for protein kinase C, 9-11 putative Ser/Thr phosphorylation sites 
for casein kinase II and 1-2 putative Tyr sites potentially for tyrosine kinase (76). A 
number of studies have been devoted to determining the quantity and location of the 
phosphorylation sites of BSP in vitro and in vivo (84-87). Findings from these studies 
demonstrate the heterogeneity of phosphorylations on BSP. Although phosphorylations 
on BSP have no apparent affect on collagen-binding activity (74), these phosphate groups 
are important in the modulation of mineral formation and this will be discussed below  
1.4.3.3 Tissue Expression of Bone Sialoprotein  
 BSP expression is primarily restricted to mineralized tissues such as bone, dentin, 
cementum, enamel and mineralizing cartilage (5, 83, 88-91). However, other studies have 
described BSP to be present in non-mineralized areas such as trophoblastic cells of the 
placenta (5, 92), salivary glands (93) and platelets (94). Transcript levels for BSP are 
higher in newly formed bone and cementum than in other tissues (95, 96). However, 
maximal levels of BSP transcripts and expression are seen during embryonic bone 
formation. BSP has been shown to be concentrated at the mineralization front and cement 
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lines (boundary of an osteon) (97). Interestingly, by immunogold labeling, BSP has been 
shown to be associated with collagen fibres in mineralized tissues (98).  
 In pathological conditions, BSP is positively correlated with cancers that 
metastasize to bone such as breast (99, 100) and prostate cancers (101, 102). In addition, 
BSP has been shown to be associated with a 97 kDa protein produced by Staphylococcus 
aureus, a bacterium that infects bones and joints (103). 
1.4.3.4 Functions of Bone Sialoprotein  
 BSP is implicated in a variety of physiological functions including cell attachment 
and signaling, HA binding and nucleation and type I collagen binding (76).  
 BSP has a highly conserved RGD site important for cell/integrin binding. The 
RGD site interacts with the αvβ3 integrin, a cell-surface receptor present in osteoclasts 
(104) and osteoblasts (105). The RGD sequence has significant function because when it 
is mutated to KAE, the cell/integrin binding of osteoblasts (106), chondrocytes (107) and 
fibroblasts (105, 108) is abolished. Binding of BSP to osteoblasts promotes osteoblast 
differentiation and mineralized nodule formation (109, 110), while binding of BSP to 
osteoclast progenitor cells appears to be involved in osteoclast generation (111, 112).  
 BSP is a potent nucleator of HA crystals in agarose (33), gelatin (113) and 
collagen gels (114). There is a strong interaction between BSP and HA with the KD of 
approximately 0.85 µM (115). The two glutamic acid-rich regions (with contiguous 
glutamic acid residues) of BSP are essentially responsible for the nucleation activity (6, 
116). Both bone-extracted BSP and prokaryotic-expressed recombinant BSP (rBSP) 
lacking PTMs were capable of nucleating HA; however, rBSP was much less potent 
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(100-fold decrease in nucleation potency) (6). This indicates that PTMs are not essential, 
but aid in nucleation.  
 Initially, it was believed that electrostatic interactions were responsible for BSP 
binding to collagen since type I collagen has a slightly positive charge at neutral pH (98). 
However, our previous work demonstrated electrostatic interactions are only partly 
involved in the BSP-type I collagen interaction as binding to collagen was reduced, but 
not abolished, by the addition of cations, increase in ionic strength or decrease in pH (74). 
The BSP-collagen interaction is primarily hydrophobic in nature, as the majority of 
collagen-bound BSP was eluted by acetonitrile (114). Bone-extracted BSP and rBSP 
(unmodified BSP) bound to type I collagen with approximately equal affinity, KD = 12.1 
nM and KD =14.2 nM, implying PTMs are not critical for binding.  
 Using a solid-phase binding assay and synthetic peptides, the type I collagen-
binding site and the structural aspects of collagen involved in its interaction with BSP 
were determined. The collagen-binding region on BSP was mapped to residues 18-45, a 
region rich in hydrophobic and basic amino acids and highly-conserved among species 
(74). Interestingly, previous studies from our laboratory have shown that thrombin 
cleaves rat BSP at Arg27-Tyr28, and abolishes collagen binding (114, 117). Moreover, 
BSP (114) displayed comparable binding affinities to monomeric and fibrillar type I 
collagen (KD = 13 nM), but not to heat-denatured collagen (gelatin) with a binding 
affinity (KD) of 44 nM. However, the non-helical telopeptides are not involved in BSP-
collagen interaction as pepsin treatment of collagen had no apparent effect. These 
findings suggest the BSP-type I collagen interaction requires a native triple-helical type I 
collagen structure, but does not require either collagen telopeptides or fibrils (114).  
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1.4.3.5 Binding of ECM Proteins to Type I Collagen  
 A number of ECM proteins other than BSP have been shown to bind to type I 
collagen. OPN binds type I collagen at a highly conserved region containing hydrophobic 
and acidic amino acid residues (118). The collagen-binding domain of DMP-1 has been 
identified to be two acidic-amino-acid-rich regions found at the C-terminal end of the 
protein and has a dissociation constant of 3.8 ±1.7 µM (119). A significant decrease in 
binding due to substitution of these acidic domains with neutral amino acids suggests that 
the interaction between DMP-1 and type I collagen is electrostatic in nature (119). By 
EM, DPP has been shown to bind primarily to the fibril surface at the “e” band, which is 
in the middle of the gap region (120). Using rotary-shadowing TEM, the DPP binding 
location on type I collagen has been mapped to approximately 210 nm from the N-
terminal end of the collagen molecule. This binding region corresponds to DPP covering 
residues 698 to 750, a region corresponding to an overlap region of the collagen fibril 
rather than a gap region (121).   
1.5  PURPOSE OF THE THESIS  
 The mechanism of biomineralization is currently unknown. In bone, it has been 
proposed that an acidic phosphoprotein of the ECM, when bound to type I collagen, will 
induce the nucleation of HA. BSP is an acidic non-collagenous phosphoprotein that is 
expressed primarily in mineralized tissues and has been shown to be a potent nucleator of 
HA (6, 7). BSP is secreted into the ECM by osteoblasts, where it is hypothesized that it 
binds to type I collagen in the gap regions or the regions adjacent to it where early 
mineral formation occur. The collagen-binding region on BSP, rich in only hydrophobic 
and basic amino acids, spans residues 18-45, and is highly conserved among species. 
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However, the BSP-binding region on type I collagen is unknown. The first objective of 
this thesis is to determine the BSP-binding region on type I collagen using a chemical 
cross-linking method and rotary-shadowing TEM. These methods will be discussed in 
greater detail in the next chapters.  
 Within the collagen-binding region, there is a highly conserved thrombin cleavage 
site at Arg27-Tyr28 and, upon cleavage, collagen-binding is abolished. The physiological 
relevance of this conserved thrombin-cleavage site has, however, not been fully 
elucidated. In addition to HA nucleation, BSP has been demonstrated to function as a 
signaling molecule in physiological pathways. BSP contains a highly-conserved C-
terminal RGD site that interacts with the αvβ3 integrin and has been shown to be 
important in cell adhesion and migration of osteoblast and tumour cells. Since BSP has 
been shown to be a chemotactic agent, we  hypothesize that upon bone injury, thrombin 
becomes activated, then cleaves and releases BSP into the ECM. Subsequently, BSP can 
act as a signaling molecule to recruit osteoprogenitor cells, which will differentiate into 
osteoblasts. The second objective of this thesis is to determine whether thrombin cleaves 
and releases BSP from type I collagen. The thrombin digestion reactions will be analyzed 
using SDS-PAGE, western blotting and MALDI-MS. 
 Collectively, the results from these studies are important in understanding the 
initial stages of bone mineralization which may ultimately lead to the generation of 
therapeutic agents to promote bone repair.  
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2.1 INTRODUCTION 
 A variety of approaches including electron microscopy, synthetic triple-helical 
peptides, cyanogen bromide cleavage and chemical cross-linking have been utilized by 
researchers in locating the binding site(s) of various proteins on type I collagen. Chemical 
cross-linking appears to be a useful tool for mapping the BSP-binding site on collagen for 
the reasons discussed below.  
 Chemical cross-linking is an important tool for studying protein-protein 
interactions as it allows the formation of a covalent attachment between two interacting 
proteins (1). The two chemical cross-linkers selected for studying the BSP-collagen 
interaction in this study were ρ-azidophenacyl bromide (APB) and N-[4-(ρ-
azidosalicylamido)butyl]-3’-(2’-pyridyldithio) propionamide (APDP). Both are 
heterobifunctional cross-linkers possessing two different functional groups separated by a 
spacer arm. APB has a bromoacetyl group, whereas APDP contains a pyridyl disulfide. 
These functional groups are electrophilic, which makes them prone to react with the 
cysteine residues (strong nucleophiles) found in the genetically modified single-cysteine 
rBSP (1-100) peptides. The second functional group is a photoactivable group that non-
specifically inserts or adds to carbon-hydrogen or nitrogen-hydrogen bonds upon UV 
exposure (1). It is advantageous for the cross-linkers to have this non-specific 
photoactivable functional group because the type I collagen region that is in close 
proximity in the BSP-cross-linker complex is unknown. The primary difference between 
the chemical cross-linkers lies in the length of the spacer arm. The spacer arm of APDP is 
approximately 2.1 nm (2) while APB has a spacer arm less than 1.2 nm in length (3). The 
longer spacer arm of APDP may potentially interact with preferred amino acid residues 
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on type I collagen that are further away from the BSP-collagen binding site and therefore 
may increase the chances of forming BSP-type I collagen cross-linked products. In 
addition, chemical cross-linking should not disrupt the triple-helical type I collagen 
structure that is essential for binding to BSP (4). Furthermore, when chemical cross-
linking is coupled with mass spectrometry (MS), the precise amino acid sequences 
involved in the interactions can be determined.  
 The purpose of the present study is to use a chemical cross-linking method to map 
the BSP-binding site on collagen. These experiments involve five single-cysteine rBSP 
(1-100) mutants generated by site-directed mutagenesis, type I collagen and the chemical 
cross-linkers: APB and APDP. Multiple approaches were taken to maximize the 
efficiency of cross-linking and recovery of BSP-type I collagen cross-link products. 
2.2  MATERIALS AND METHODS  
2.2.1  MATERIALS 
 For protein expression and purification, E.coli (DE3) cells were purchased from 
EMD Biosciences/Novagen (Gibbstown, NJ). Medical grade N2 was obtained from 
Praxair Inc. (Mississauga, ON). Isopropyl β-D-thiogalactopyranoside (IPTG) was 
purchased from Sigma-Aldrich (St. Louis, MO). Urea UltraPure grade was from BioShop 
Canada (Burlington, ON).  
 For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE): 
ammonium persulfate (APS), N, N, N’, N’-tetramethylethane-1, 2-diamine (TEMED), 
acrylamide/bis-acryalmide, SDS and pre-stained protein standards were all purchased 
from Bio-Rad Laboratories (Hercules, CA). β-mercaptoethanol and glycine were 
obtained from Thermo Fisher Scientific (Rockford, IL). Isopropanol was from VWR 
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International (West Chester, PA). Imidazole, Stains-All and silver nitrate were all 
purchased from Sigma-Aldrich. 
 For chemical cross-linking, the cross-linkers: APDP was purchased from Thermo 
Fisher Scientific while APB was purchased from Sigma-Aldrich. The reducing agent, 
Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) was from Sigma-Aldrich. For 
dissolving the chemical cross-linkers, dimethylformamide, (DMF) and methanol were 
obtained from VWR International. Type I collagen was extracted from rat tail tendons in 
our laboratory as previously described (5). 
2.2.2 METHODS 
2.2.2.1 Expression and purification of rBSP (1-100) mutants  
 A schematic diagram of BSP depicting the amino acids mutated to cysteine is 
shown in Figure 2.1. The plasmids of the five single-cysteine mutants were generated by 
site-directed mutagenesis by Aaron Langdon (past MSc student in Drs. Goldberg and 
Hunter’s Laboratories). Three of the five single-cysteine rBSP (1-100) mutants (S16C, 
Y31C and Y24C) were present in adequate amounts in the laboratory for the chemical 
cross-linking experiments while the remaining two single-cysteine mutants (F36C and 
S49C) were expressed and purified as described below.  
 The two single-cysteine rBSP (1-100) mutants (F36C and S49C) contain a penta-
His fusion tag at the C-terminus and were transformed into E.coli BL21 (DE3) cells and 
grown in Luria broth (LB) containing 15 µg/ml kanamycin. When the optical density of 
the cells reached 0.6 – 0.8, the cells were induced with 2 mM IPTG and grown for an 
additional 4 hours. Sonication in His-column binding buffer (5 mM imidazole, 0.5 M 
NaCl, 0.02 Tris-HCl, 6 M urea, pH 7.9) was used to lyse the bacterial cells. 
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Subsequently, the cell lysate was fractionated by centrifugation and the supernatant 
recovered.  
  The single-cysteine rBSP (1-100) mutants were purified extensively. The first 
purification step was nickel affinity chromatography. The cell extract was loaded onto 
Poly-prep chromatography columns (Bio-Rad) packed with 1.5 ml His-bind resin 
(Novagen) that had been previously charged with 50 mM NiSO4. The columns were first 
washed with 10 column volumes of binding buffer and the proteins eluted with 500 mM 
imidazole-containing elution buffer (binding buffer containing 500 mM imidazole). The 
eluted fractions were separated on 12.5% polyacrylamide gels using the Phastgel system 
(Amersham Biosciences) and the gels stained with Stains-All (30 mM Tris-HCl pH 8.0, 
7.5% formamide, 25% isopropanol, and 0.0025% Stains-All) and silver nitrate as 
previously described (6). 
 The protein-enriched fractions from nickel affinity were pooled and diluted with 
Mono A buffer (50 mM Tris-HCl, 7M urea, pH 7.4) and purified further by ion-exchange 
chromatography. The fractions were loaded onto a Q Sepharose Fast Flow 1 x 10 cm 
column (Fast Q) connected to the Fast Protein Liquid Chromatography (FPLC) system 
(AKTA-purifier Amersham Pharmacia Biotech). Proteins were eluted with a linear 
gradient of sodium chloride (0 – 500 mM) at a flow rate of 2.0 ml/min. Fractions of 1 ml 
were collected and selected fractions stained with Stains-All and silver. Fractions 
containing the peptide of interest were pooled and concentrated to a volume of 
approximately 2.5 ml using a pressurized Amicon ultrafiltration apparatus with an YM-3 
(3-kDa cutoff) membrane (Millipore).  
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 The concentrated protein-enriched fractions were purified further by gel filtration 
using a Superdex 200PG column (1.6 cm x 60 cm) (Amersham Biosciences) in 50 mM 
Tris, 4 M urea, 200 mM NaCl, pH 7.4. The fractions containing the protein of interest 
(determined by SDS-PAGE) were dialyzed using 10 mM ammonium bicarbonate for 72 
hours at 4° C using a 3-kDa cutoff Spectra/Por dialysis membrane (Spectrum 
Laboratories). After dialysis, the fractions were aliquoted and lyophilized. Finally, the 
purity and quantity of the protein samples were determined by Bicinchoninic acid (BCA) 
assays, amino acid analysis (Advance Protein Technology Centre, The Hospital for Sick 
Children, Toronto) and MALDI mass spectrometry (Bruker® Reflex IV  MALDI TOF 
MS, Department of Biochemistry, UWO, London).  
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Figure 2.1 Schematic diagram of BSP depicting the amino acids mutated to cysteine. 
BSP contains approximately 300 amino acid residues (as indicated by the numbers). The 
amino acids mutated to cysteine for chemical cross-linking are highlighted in orange. The 
selected amino acids are within and surrounding the collagen-binding region.  
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2.2.2.2 Chemical Cross-Linking with APB and APDP and Purified using 
 TALON® His6-Tag Cobalt Resin 
   
 A general overview of the chemical cross-linking protocol is shown in Figure 2.2.  
 Chemical cross-linking reactions between single-cysteine rBSP mutants (S16C, 
Y24C, Y31C, F36C and S49C) and type I collagen were carried out using 
heterobifunctional cross-linkers APB and APDP. Additionally, control cross-linking 
reactions between wild-type (WT) rBSP (1-100) and type I collagen using APB and 
APDP were performed. These reactions served as the control as WT rBSP (1-100) does 
not contain a cysteine residue that is required for cross-linking to occur.    
 First, bond-breaker solution (9 mM TCEP in 2x PBS) was added to single-
cysteine BSP (1-100) mutants (1 mg/mL dissolved in 2x PBS, 3 mM EDTA pH 7.5) and 
incubated for 30 min. Subsequently, the bond-breaker solution was removed by buffer 
exchange using Amicon® Ultra-0.5 centrifugal filter units. The single-cysteine BSP 
mutants were incubated with one of the chemical cross-linkers: 50 mM APDP in DMF or 
50 mM APB in methanol for 30 min in the dark. Excess cross-linkers were then removed 
by buffer exchange using Amicon® Ultra-0.5 centrifugal filter units.  Type I collagen (1 
mg/mL) in 5 mM acetic acid was then added to the reaction mixture and incubated in the 
dark for 1 hour. To induce chemical cross-link formation, the reaction mixture was 
irradiated with a UV ultraviolent lamp (Thermo Scientific Pierce) at a wavelength of 365 
nm for APDP and at 254 nm for APB for 5 min.  
 In order to maximize the recovery of successful BSP-type I collagen cross-link 
products, reactions were purified using TALON® His6-Tag cobalt resin (Clontech 
Laboratories) and concentrated using Amicon® Ultra-4 centrifugal filter units and 
Amicon® Ultra-0.5 centrifugal filter units. The reactions were loaded onto a 6% SDS-
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PAGE gel in the absence of a reducing agent and run at 80 V until the separating gel was 
reached where the voltage was increased to 120 V. The gels were then stained with 
Stains-All and silver (6) for analysis. 
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Figure 2.2 An overview of the chemical cross-linking protocol. Chemical cross-linking 
reactions between single-cysteine rBSP (1-100) mutants and type I collagen were carried 
out using the cross-linkers APB or APDP. The chemical cross-linking reactions were 
purified using a His6 –Tag cobalt resin or nickel magnetic beads and then concentrated 
using centrifugal filter devices. The products of the cross-linking reactions were then 
analyzed using Stains-All and silver. 
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2.2.2.3  Chemical Cross-Linking using APDP and Purification using Millipore  
 PureProteome
TM
Nickel Magnetic Beads  
  
 In hopes to increase the recovery of successfully cross-linked BSP-type I collagen 
complexes, the purification resin was changed from the TALON® His6-Tag cobalt resin 
(Clontech Laboratories) to nickel magnetic beads (Millipore PureProteome
TM
). 
 Chemical cross-linking reactions between single-cysteine BSP mutants (S49C and 
F36C) and type I collagen were carried out using APDP as previously described. The 
single-cysteine mutants, S49C and F36C, were used for this experiment as these two 
mutants showed higher levels of potential cross-links over the other single-cysteine 
mutants. Additionally, the cross-linker APDP was used rather than APB for the same 
reasons.  
  After chemical cross-linking, the reactions were purified using an aliquot of 200 
µL of nickel magnetic beads present in a 1.5 mL microcentrifuge tube. The magnetic 
beads were first equilibrated with 500 µL of equilibration buffer (50 mM sodium 
phosphate, 300 mM NaCl, pH 8) for 1 min at 22°C. The equilibration buffer was 
removed by placing a small circular magnet (Staples®, Canada) at the side of the 
microcentrifuge tube, resulting in the magnetic beads adhering to the side of the tubes 
allowing for the buffer to be easily removed by a pipette. The protein sample was then 
added to the magnetic beads and incubated for 1 hour at 22°C. Subsequently, five 
consecutive washes using the wash buffer (50 mM sodium phosphate, 300 mM NaCl, pH 
8) were performed to remove any unbound proteins. Elution of the protein was done by 
adding an aliquot of 100 µL of elution buffer (50 mM sodium phosphate, 300 mM 
sodium chloride, 300 mM imidazole, pH 8) and incubation for 2 min at 22°C. The eluted 
fraction was collected with use of the magnet and the recovered solutions concentrated 
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and analyzed by SDS-PAGE and staining with Stains-All and silver (as previously 
described) for analysis of potential BSP-type I collagen cross-links.  
2.2.2.4 Characterization of the Additional Bands after Chemical Cross-Linking 
 To determine whether the high-molecular-weight bands present after chemical 
cross-linking are rBSP (1-100) cross-linked to itself, cross-linking reactions were carried 
out with the single-cysteine rBSP (1-100) F36C mutant and type I collagen using APDP 
as previously described. The single-cysteine rBSP (1-100) F36C mutant was chosen for 
this experiment as this mutant showed high levels of the high-molecular-weight bands 
after cross-linking. Prior to loading the samples onto a 6% SDS-PAGE gel, the samples 
were heated to 95°C in the presence or absence of a reducing agent (β-mercaptoethanol) 
for 10 min. In the case where the bands are a result of the single-cysteine rBSP (1-100) 
mutants self-cross-linking, the disulfide bonds will break in the presence of β-
mercaptoethanol and the polymeric BSP will be reduced to monomeric rBSP (1-100) 
peptides.  The gel was then stained with Stains-All and silver for analysis. Additionally, 
to ensure that the sensitivity and detection of type I collagen is not decreased with Stains-
all and silver, a second 6% SDS-PAGE gel was stained with only silver nitrate (6). 
2.2.2.5 Chemical Cross-Linking using APDP and Purification using Gel 
 Filtration and Millipore PureProteome
TM
 Nickel Magnetic Beads  
 
 Another attempt to increase the recovery of successful BSP-type I collagen cross-
linked polymers was to use two purification approaches: gel filtration and nickel 
magnetic beads. Chemical cross-linking reactions between the single-cysteine BSP 
mutant (S49C) and type I collagen were carried out using APDP as previously described. 
Prior to purification of the cross-linking reactions using nickel magnetic beads, the 
reaction mixture was purified by gel filtration on a Superdex 200PG column. This step 
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should separate the lower-molecular-weight single-cysteine rBSP (1-100) mutants that 
are not cross-linked to collagen from larger-molecular-weight cross-linked polymers. The 
removal of the potentially competing binding ligand for the nickel resin should enhance 
binding and recovery of rBSP-type I collagen cross-linked products.  Furthermore, the 
higher-molecular-weight fractions containing the co-eluting unbound type I collagen 
should not bind to the nickel resin since it does not contain the His6).   
2.3 RESULTS 
2.3.1  Expression and purification of rBSP (1-100) mutants  
 Two single-cysteine rBSP (1-100) mutants (F36C and S49C) were overexpressed 
in E.coli BL21 (DE3) cells and purified extensively using three purification columns. The 
first purification step was nickel affinity chromatography. The eluted fractions were 
separated on 12.5% polyacrylamide gels and stained with Stains-All and silver to 
determine the purity of the fractions (results not shown).  
 The protein-enriched fractions from nickel affinity were pooled and further 
purified by ion exchange using a Fast Q column connected to the FPLC system. The 
presence of proteins was monitored spectrophotometrically at 230 and 280 nm (Figure 
2.3A). Selected fractions were separated on 12.5% polyacrylamide gels and stained with 
Stains-All and silver for analysis (Figure 2.3A, insert).  
 The protein-enriched fractions from ion exchange were pooled and loaded onto a 
Superdex 200PG column and monitored spectrophotometrically at 230 and 280 nm for 
the presence of protein (Figure 2.3B). The fractions containing the protein of interest 
(Figure 2.3B, insert) were dialyzed against 10 mM ammonium bicarbonate and then 
aliquoted and lyophilized. 
52 
 
 The purity of the protein samples were further verified by MALDI mass 
spectrometry. The single-cysteine rBSP (1-100) F36C mutant with a 5xHis tag was 
detected by MALDI mass spectrometry as a single peak at 12,029 Da. The theoretical 
mass based on the known amino acid sequence is 12,036 Da. Additionally, the quantity 
of the protein samples were determined by BCA assays (data not shown). 
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Figure 2.3 Chromatograms of the single-cysteine rBSP (1-100) F36C mutant 
separated by ion exchange and gel filtration chromatography.  
 
The protein-enriched fractions from nickel affinity were pooled and diluted with Mono A 
buffer (50 mM Tris-HCl, 7 M urea, pH 7.4) and loaded onto a (A) Fast Q packed column 
connected to the FPLC system. Proteins were eluted with a linear gradient of 0-0.5 M 
NaCl. Fractions of 1 mL were collected and selected fractions (green box) were purified 
further with a (B) Superdex 200PG gel filtration column. The fractions containing the 
protein of interest were pooled and lyophilized (green box). The absorbance at 280 nm is 
in blue and the absorbance at 230 nm is in red.  
 
 
B 
A 
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2.3.2 BSP-type I collagen cross-linking reactions using APB  
 Chemical cross-linking between the five single-cysteine rBSP (1-100) mutants 
was carried out using APB. Subsequently, type I collagen (1 mg/ml) in 5 mM acetic acid 
was then added to the reaction mixture. The products of the cross-linking reactions were 
loaded onto a 6% SDS-PAGE and analyzed by Stains-All and silver (Figure 2.4).   
 The band corresponding to the single-cysteine rBSP (1-100) mutants appears near 
18 kDa on SDS-PAGE, even though the actual molecular weight (based on the known 
amino acid sequence) is approximately 12.2 kDa. With regards to type I collagen, the 
molecular weight of each collagen α-chain is approximately 97 kDa (based on the known 
amino acid sequence), however; based on SDS-PAGE, the α1 and α2 chains migrate much 
slower than expected: at approximately 120 kDa and 110 kDa, respectively. From the 
known molecular weights of the rBSP (1-100) mutants and the collagen α-chains, a 
successful cross-link would be approximately 110 kDa.  
 However, due to the slow migration of rBSP (1-100) mutants and collagen α 
chains, the successful BSP-type I collagen cross-link would be in the range of 128 kDa to 
138 kDa.  Therefore, a band corresponding to a successful cross-link BSP-collagen 
product would be immediately above the α1 and α2 chains of type I collagen (Figure 2.4; 
the lanes labeled “coll” indicate the position of the α1 and α2 chains). There appears to be 
a band present, albeit weakly-stained, at approximately 130 kDa that may correspond to a 
BSP-collagen cross-link (Figure 2.4; as indicated by the purple arrow). Furthermore, this 
possible cross-link at 130 kDa was not observed in the control cross-linking reactions 
using rBSP (1-100). However, there are numerous additional bands above and below 130 
kDa. As well, the generally weakly stained band suggests recovery of the cross-linked 
protein is low and/or the cross-linking efficiency is low. 
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Figure 2.4 Analysis of BSP-type I collagen cross-linking reactions using APB.   
Chemical cross-linking reactions between single-cysteine BSP mutants (S16C, Y24C, 
Y31C, F36C and S49C) and type I collagen were carried out using APB. Reactions were 
purified using TALON® His6-Tag cobalt resin and concentrated using Amicon® Ultra-4 
centrifugal filter units and Amicon® Ultra-0.5 centrifugal filter units prior to loading 
onto a 6% SDS-PAGE gel and stained with Stains-All and silver for analysis. Potential 
cross-links between BSP and collagen are present at approximately 130 kDa (purple 
arrow).  “M” indicates the molecular marker; rBSP refers to the wild type peptide. 
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2.3.3 BSP-Type I Collagen Cross-Linking Reactions using APDP  
 An attempt was made to increase the cross-linking efficiency between BSP and 
type I collagen by using APDP (2.1 nm), which contains a longer spacer arm than APB 
(1.2 nm).  
 Once again, there appears to be a band, albeit weakly stained, at approximately 
130 kDa corresponding to a potential BSP-collagen cross-link (Figure 2.5; as indicated 
by the purple arrow). Furthermore, this possible cross-link at 130 kDa was not observed 
in the control cross-linking reactions using rBSP (1-100). However, the same issues are 
evident: there are additional bands above and below the potential cross-linked product. 
Additionally, the weakly stained band suggests recovery of the cross-linked protein is 
low and/or the cross-linking efficiency is low.  
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Figure 2.5 Analysis of BSP-type I collagen cross-linking reactions using APDP.   
Chemical cross-linking reactions between single-cysteine rBSP mutants (S16C, Y24C, 
Y31C, F36C and S49C) and type I collagen were carried out using APDP. Reactions 
were purified using TALON® His6-Tag cobalt resin, concentrated by centrifugal 
ultrafiltration, and analyzed by 6% SDS-PAGE and staining with Stains-All and silver. 
Potential cross-links between BSP and collagen are present at approximately 130 kDa 
(purple arrow). “M” indicates the molecular-weight marker. 
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2.3.4 BSP-Type I collagen Cross-Linking Reactions using APDP and 
Purified using Millipore PureProteome
TM
 Nickel Magnetic Bead 
 
 In hopes to enhance the cross-linking efficiency, the purification resin was 
changed from the TALON® His6-tag cobalt resin to Millipore PureProteome
TM
 nickel 
magnetic beads. Chemical cross-linking reactions between single-cysteine rBSP mutants 
(S49C and F36C) and type I collagen were carried out using APDP as previously 
described. 
 Unfortunately, no increase in the recovery of the cross-linked products was 
observed (as indicated by the weakly stained band at approximately 130 kDa; Figure 2.6). 
As well, there are additional bands above and below the potential BSP-type I collagen 
cross-link present, suggesting this purification resin did not increase the recovery of the 
cross-linked products in the expected manner.  
2.3.5 Characterization of the Additional Bands Present after Cross-
Linking 
 
 To determine whether the additional bands above and below the potential BSP-
collagen cross-link in Figures 2.4 and 2.5 are the result of the single-cysteine rBSP (1-
100) mutants cross-linking to itself, chemical cross-linking reactions with F36C, WT 
rBSP (1-100) and type I collagen were performed using APDP. Prior to loading the 
samples onto a 6% SDS-PAGE gel, the samples were heated to 95°C in the presence or 
absence of a reducing agent (β-mercaptoethanol) for 10 min. The gels were stained with 
Stains-All (Figure 2.7A), the combined Stains-All silver protocol (Figure 2.7B) or only 
silver (Figure 2.7C). 
 The additional bands, above and below the potential cross-linked product (Figure 
2.7A and 2.7B yellow box) from samples not treated with β-mercaptoethanol, were not 
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observed when β-mercaptoethanol was added (Figure 2.7A and 2.7B; green box). As 
well, the blue smear present with Stains-All in the absence of β-mercaptoethanol is 
indicative of an acidic protein (Figure 2.7A). These findings suggest the bands are a 
result of the single-cysteine rBSP (1-100) mutants cross-linking to itself.  
 The 6% SDS-PAGE stained with silver nitrate alone (Figure 2.7C), ensured that 
sensitivity and detection of type I collagen is not decreased with Stains-All and silver. No 
apparent differences are observed between the two staining protocols.  
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Figure 2.6 Analysis of BSP-type I collagen cross-linking reactions using APDP and 
purified using nickel magnetic beads. 
 
Chemical cross-linking reactions between single-cysteine BSP mutants (S49C and F36C) 
and type I collagen were carried out using APDP. Reactions were purified using the 
nickel magnetic beads (Millipore PureProteome
TM
) and concentrated by centrifugal 
ultrafiltration prior to loading onto a 6% SDS-PAGE gel and staining with Stains-All and 
silver for analysis. “M” indicates the molecular marker. 
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Figure  2.7 Characterization of the additional bands present after cross-linking. 
Chemical cross-linking was carried out using F36C, WT rBSP (1-100) and type I 
collagen using APDP to determine whether the bands observed in (Figures 2.4 and 2.5) 
are the result of single-cysteine rBSP mutants self-cross-linking. Prior to loading the 
samples onto a 6% SDS-PAGE gel, the samples were heated to 95°C in the presence or 
absence of β-mercaptoethanol. The gels were then stained first with (A) Stains-All and 
followed by (B) silver for analysis. The bands that appear as a blue smear (yellow box) 
are the result of single cysteine rBSP (1-100) F36C mutant cross-linking to itself and are 
reduced to monomeric rBSP (1-100) F36C in the presence of β-mercaptoethanol (green 
box). Identical samples were electrophoresed on a second 6% SDS-PAGE gel and stained 
with silver only (C). “M” indicates the molecular marker. 
A B 
C 
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2.3.6 BSP-type I collagen cross-linking reactions using APDP and 
purified using gel filtration and nickel magnetic beads 
 
 In order to increase the recovery of successful BSP-type I collagen cross-linked 
polymers, two purification approaches were used: gel filtration and nickel magnetic 
beads. Chemical cross-linking reactions between the single-cysteine BSP mutant (S49C) 
and type I collagen were carried out using APDP as previously described. Prior to 
purification of the cross-linking reactions using nickel magnetic beads, the reaction 
mixture was separated by gel filtration on a Superdex 200PG column. This step separated 
the single-cysteine rBSP (1-100), and the smaller rBSP (1-100) polymers that were not 
cross-linked to collagen from larger molecular weight cross-linked polymers. The 
fractions consistent with containing BSP-type I collagen cross-links were collected 
(Figure 2.8A, orange box), and purified further using the nickel magnetic beads. 
Unfortunately, from the gel electrophoresis analysis, no increase in the efficiency of the 
cross-linked products was observed using this approach (Figure 2.8B).  
 
 
 
 
 
 
63 
 
 
 
 
Figure 2.8 BSP-type I collagen cross-linking reactions using APDP and purification 
by gel filtration and nickel magnetic beads. 
 
Chemical cross-linking reactions between the single-cysteine BSP mutant (S49C) and 
type I collagen were carried out using APDP. The cross-linking reactions were purified 
by gel filtration and nickel magnetic beads. (A) Gel filtration on a Superdex 200PG 
column. The fractions potentially containing BSP-type I collagen cross-links were 
collected (A; orange box) and purified further using nickel magnetic beads. The purified 
samples were then loaded onto a 6% SDS-PAGE gel and stained with (B) Stains-All and 
silver for analysis. “M” indicates the molecular-weight marker. 
B 
A 
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2.4 DISCUSSION  
 Chemical cross-linking is a good protocol for mapping the BSP-binding region on 
type I collagen as it allows the formation of a covalent attachment between two 
interacting proteins. A major advantage is that when coupled with MS it facilitates the 
determination of the BSP-binding site on collagen to the amino-acid level. Once the 
covalent cross-linked product is characterized by MS, our goal would have been to use 
molecular modeling (MM) to simulate the BSP-type I collagen interaction and to pinpoint 
the interacting amino acids (7).   
 Multiple approaches were taken to maximize the efficiency and/or recovery of 
successful BSP-type I collagen cross-linked products. However, the efficiency and/or 
recovery of the cross-linked products observed from the gels stained with Stains-All and 
silver were unexpectedly low in all instances and therefore the complexes were not 
further characterized.  
2.4.1 Single-cysteine rBSP (1-100) mutants 
 To maximize the chances of a successful BSP-type I collagen cross-link, five 
single-cysteine mutants were generated. The residues selected for cysteine substitutions 
are within and surrounding the type I collagen-binding domain in BSP. Within the 
collagen-binding region, the residues selected for cysteine substitution (Y24, Y31 and 
F36) are bulky, aromatic residues and were chosen in order to minimize steric hindrance 
between rBSP (1-100) peptides and collagen in the presence of cross-linker agents. 
Residues surrounding the collagen-binding domain were selected in case the mutations 
within the collagen-binding region interfered with the BSP-collagen interaction. The 
residues selected for cysteine substitution (S16 and S49) had chemically similar side-
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chains as steric hindrance was less of a consideration. Additionally, the selected residues 
on BSP were mutated to cysteine as BSP does not contain any cysteine residues and 
therefore it is known where on the protein the cross-linker would be bound. 
2.4.2 BSP-type I collagen cross-linking reactions using APB and APDP  
 There was a possible BSP-collagen cross-link at approximately 130 kDa when the 
cross-linkers APB and APDP were used. The presence of weakly stained bands suggests 
the cross-linking efficiency and/or recovery of the cross-linked products is low. This was 
unexpected as the chemical cross-linkers APB and APDP have been used in many cross-
linking experiments studying protein-protein interactions. APB has been utilized to 
identify the binding sites within the b subunit of E.coli ATP synthase that are responsible 
for interacting with α, β, and a subunits (8). APB was also used to study the interaction 
between yeast cytochrome c and cytochrome c peroxidase (9). With regards to APDP, 
this cross-linker has been utilized by Yasui et al. to study the interaction between a 
pigment epithelium-derived factor (PEDF) and type I collagen (10).   
 In addition, multiple steps were taken to maximize the cross-linking efficiency 
and recovery of the successful BSP-collagen cross-linked complex. Following the 
reaction of APB or APDP with single-cysteine rBSP (1-100) mutants, excess cross-
linkers were removed by buffer exchange. This step was carried out to reduce non-
specific cross-link formation. Additionally, following UV exposure to induce cross-link 
formation, the reactions were affinity purified and concentrated. These two steps were 
carried out to maximize the recovery of successful BSP-type I collagen cross-link 
products.  
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 It is also puzzling that there are unbound α1 and α2 collagen chains present since 
the cross-linking reaction products were affinity purified to recover the poly-His-
containing proteins. A potential explanation for this is that collagen bound non-
specifically to the purification resin.  Therefore a different purification protocol was used, 
as discussed below. 
2.4.3 Chemical cross-linking using APDP and purification using nickel 
magnetic beads  
 
 Using nickel magnetic beads we observed no increase in the amount of the BSP-
collagen cross-linked products (Figure 2.6). This was unexpected since the nickel 
magnetic beads have been shown to achieve high purity and yield of His6-tag proteins 
(11, 12). The single-cysteine mutants, S49C and F36C were used for this experiment 
because they showed higher levels of potential cross-links over the other single-cysteine 
mutants. Additionally, the cross-linker APDP was used rather than APB for the same 
reasons. However in spite of all the modifications, cross-linked product was not evident 
in high yield. A potential explanation of why this purification resin did not enhance the 
recovery lies in the additional bands present after chemical cross-linking.   
2.4.4 Characterization of the additional bands present after cross-
linking 
 
 Since the additional bands (in the absence of β-mercaptoethanol) were not 
observed when β-mercaptoethanol (disulfide bond ‘breaker’) was added (Figure 2.7A and 
2.7B; green box), these bands are likely a result of the single-cysteine rBSP (1-100) 
mutants cross-linking to itself.  Additional evidence that the bands are a result of the 
single-cysteine rBSP (1-100) mutants cross-linking to itself is the blue staining of these 
higher molecular weight bands with Stains-All, which is indicative of an acidic protein.  
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Since there was a concern that excess rBSP peptide, both unreacted and cross-linked to 
itself, would interfere with the rBSP-collagen product binding to the nickel affinity 
column, a strategy to remove the majority of the unwanted peptide was developed. 
2.4.5 BSP-type I collagen cross-linking reactions using APDP and 
purified using gel filtration and nickel magnetic beads 
 
 No increase in the amount of the higher molecular weight recovered cross-linked 
products was observed when the single-cysteine rBSP (1-100) mutants and smaller 
polymeric BSP that are not cross-linked to collagen were first removed by gel filtration 
(Figure 2.8B). However, the low level of BSP-collagen cross-linked products observed is 
not likely due to the cysteine residues being unreactive. Previous work with fluorescein-
5-maleimide demonstrated that the cysteine residues found in the single-cysteine (1-100) 
rBSP peptides are available and able to react with the chemical cross-linkers 
(unpublished data).  A potential explanation for the low BSP-collagen cross-linked 
products lie in the spacer arm, perhaps it was not long enough to reach a collagen amino 
acid from the cysteine residue of the single-cysteine rBSP (1-100) peptide. However, 
these two cross-linkers possess the longest spacer arms among commercially available 
heterobifunctional cysteine-reactive cross-linkers with a photoactivable group. For 
example, benzophenone-4-maleimide (BPM) has a spacer arm that is less than 0.9 nm. In 
addition, BPM has a photoactivable group that has been shown to have a preference for 
methionine residues. This may potentially decrease the BSP-collagen cross-linked 
products formed as methionine residues are fairly spread out within collagen molecules 
(13). In order to increase the sensitivity of detection, some researchers have utilized 
trifunctional cross-linkers possessing a biotin group such as sulfosuccinimidyl-2-[6-
(biotinamido)-2-(p-azidobenzamido)-hexanoamido] ethyl-1,3=-dithiopropionate (sulfo-
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SBED) (14, 15). Subsequently, the cross-linked products would be enriched through 
affinity chromatography. However, since the cross-linking efficiency is low; this 
approach would require a sufficiently large amount of protein in order to obtain the 
desired amount BSP-collagen cross-linked product. Therefore, due to these difficulties in 
obtaining sufficient BSP-collagen cross-linked product, an alternative protocol using 
rotary-shadowing transmission electron microscopy (rotary-shadowing TEM) was used to 
map the BSP-binding site on type I collagen (discussed in the next chapter). 
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3.1 INTRODUCTION 
 Rotary-shadowing transmission electron microscopy (rotary-shadowing TEM) is 
an excellent tool for identifying protein binding sites on other proteins because it offers 
high-contrast visualization of individual macromolecules. This is made possible by 
evaporation of a contrast-enhancing metal (e.g. platinum) that produces a fine grain onto 
the specimens at a low angle (i.e. 5-15°) (1-3). Researchers have utilized rotary-
shadowing TEM extensively for locating the type I collagen-binding site(s) of various 
proteins such as proteoglycans, dentin phosphophoryn (DPP) and integrins (4-7). For 
instance, rotary-shadowing TEM shows DPP, a proposed mediator of mineralization in 
dentin, binding to type I collagen at a distance that is approximately 210 nm from the N-
terminal end of the collagen molecule. This corresponds to DPP covering residues 698 to 
750 on collagen upon binding (an overlap region of the collagen fibril) (4). Using gold-
labeling EM, San Antonio et al., mapped the heparin-binding location to the N-terminal 
region of collagen (5). This method has also been used to map the collagen-binding sites 
for integrins α1β1 and α2β1 (6). Similarly, decorin has been mapped to a region near the C-
terminus, which corresponds to the c1 band in the overlap region of the collagen fibril D-
period (7). Collectively, these studies demonstrate rotary-shadowing TEM to be a 
promising tool for studies of protein interactions with collagen.  
 Since studies on chemical cross-linking of BSP to type I collagen were hampered 
because of low yield, rotary-shadowing TEM was used to visualize the BSP-binding site 
on type I collagen.  Using this method, the structures of type I collagen (8) and BSP (9) 
have been successfully elucidated by others. Type I collagen appears semi-flexible and 
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rod-like, while BSP appears as a monomer with a 10-nm globular structure that is linked 
to an elongated thread-like structure of ~25 nm.   
3.2  MATERIALS AND METHODS  
3.2.1 MATERIALS 
 Type I collagen was either extracted from rat tail tendons [as previously described 
(10)], or obtained commercially from Sigma-Aldrich (St. Louis, MO).  TEM copper 
grids, 400 mesh, and mica were from Electron Microscopy Sciences (Hatfield, PA). 
Ammonium formate and acetic acid were purchased from Sigma-Aldrich. Glycerol was 
from EMD Biosciences/Novagen (Gibbstown, NJ). Carbon rods and platinum were 
purchased from SPI Supplies (West Chester, PA).  
3.2.2  METHODS  
3.2.2.1 Rotary-shadowing TEM  
 A general overview of the protocol is illustrated in Figure 3.1. 
 The interaction of BSP and type I collagen was examined using glycerol-
spraying/low-angle rotary-shadowing TEM (2, 3) at The Microscopy Imaging Laboratory 
(University of Toronto). Full-length rBSP was dissolved in 70% glycerol/30% 0.01 M 
ammonium formate to a final concentration of 50 µg/ml. Type I collagen (1 mg/ml 
prepared in-house or 1 mg/ml obtained from Sigma) was stored in acetic acid, and 
dialyzed with 0.01 M ammonium formate, pH 7.2, prior to use. An anti-collagen I 
antibody (Sigma) used to identify the N-terminal end of the collagen molecules was 
diluted to 5 µg/ml in 70% glycerol/30% 0.01 M ammonium formate (v/v).   
 The samples prepared for rotary-shadowing TEM are outlined in Figure 3.2. An 
aliquot of 10 µl of each sample was mixed together in a microcentrifuge tube, vortexed 
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and incubated overnight at 4°C. A 20 µl aliquot of the sample mixture was then sprayed 
onto freshly cleaved mica sheets (Electron Microscopy Sciences) with a pressurized 
duster (Lyreco, Markham ON) at a distance of approximately 30 cm. In addition, the 
sample buffer (70% glycerol/30% 0.01 M ammonium formate) was rotary-shadowed and 
served as a control. Micas with the samples were then dried in vacuum and rotary-
shadowed with platinum with an electron-bombarded source at an angle of 5°. 
Subsequently, the samples were backcoated at 90° with a carbon film. The films were 
then floated off the mica and transferred onto three 400-mesh TEM copper grids for 
analysis in a Philips CM-10 TEM at the UWO Biotron operating at 80 kV. The images 
were taken using the AMT Image software and measurements were made with the 
ImageJ software (NIH).  
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Figure 3.1 An overview of the rotary-shadowing TEM protocol. 
 Full-length rBSP (50 µg/ml) and type I collagen (1mg/ml) were incubated overnight at 4 
°C and then sprayed onto freshly cleaved mica sheets. Mica containing the samples were 
then rotary-shadowed with platinum and backcoated with a carbon film. The films were 
then floated off the mica and transferred onto 400-mesh copper grids for TEM analysis. 
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Figure 3.2 Sample preparations for rotary-shadowing TEM.  
The different sample preparations for rotary-shadowing TEM using rBSP (50 µl/ml), two 
sources of type I collagen (prepared in-house and purchased from Sigma), and a N-
terminal type I collagen antibody (5 µg/ml) are shown. 
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3.3 RESULTS  
3.3.1 Rotary-shadowing TEM of recombinant BSP 
 Rotary-shadowing TEM shows rBSP as a monomer possessing a 10-nm globular 
structure linked to an elongated thread-like structure of ~25 nm (Figure 3.3B). The 
schematic diagram in (Figure 3.3C) illustrates the shape of rBSP particles found in 
(Figure 3.3B), which is consistent with the literature (9).  
3.3.2 Type I collagen rotary-shadowed with platinum 
 Two sources of type I collagen (prepared in-house and purchased from Sigma) 
were rotary-shadowed with platinum. The TEM images in (Figure 3.4) show 
representative type I collagen molecules observed upon examination of more than 50 
collagen molecules (from multiple TEM copper grids) for each collagen source. The 
majority of the collagen molecules from Sigma (greater than 90%) appear semi-flexible 
and rod-like. Measurements of the collagen lengths with the ImageJ software reveal a 
mean of 270 nm and a standard deviation of 32 (at the 95% confidence level). In contrast, 
the lengths of the collagen molecules prepared in-house are quite varied. In addition to 
semi-flexible and rod-like collagen molecules, collagen molecules with lengths of 700 
nm or greater are present, possibly indicative of aggregation.  
3.3.3 N-terminal type I collagen antibodies rotary-shadowed with 
platinum 
 
 To determine the orientation of the type I collagen, antibodies recognizing the N-
terminal end of type I collagen were used. The antibodies to type I collagen after rotary-
shadowing appear as globular structures with diameters of approximately 10 nm (Figure 
3.5). 
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3.3.4 Binding of rBSP on type I collagen  
 Our initial TEM studies of the rBSP-collagen interaction involved the use of the 
in-house prepared collagen. A mixture consisting of rBSP (50 µg/ml) and type I collagen 
(5 µg/ml) was incubated overnight at 4°C and rotary-shadowed with platinum. Analysis 
of multiple TEM copper grids shows the mean rBSP binding site on type I collagen to be 
31% of the total distance from one end of the collagen molecule with a standard deviation 
of 5.58% (at the 95% confidence level) (Figure 3.6A).  Subsequently, TEM studies of the 
rBSP-collagen interaction with the collagen obtained from Sigma was completed and 
based on the results of binding of both N-terminal collagen antibody and rBSP, it appears 
rBSP binds closer to the N-terminal end (Figure 3.6B). Furthermore, this suggests that 
BSP covers a region that is approximately 315±57 (at the 95% confidence level) residues 
from the N-terminal end of the collagen molecule, corresponding to a region 
encompassing residues 258 to 372. Figure 3.6B was not included in the determination of 
the mean and standard deviation as the length of the C-terminus was not well-defined and 
therefore a significant margin of error would result. 
 After analysis of all the TEM copper grids, it was evident the main difficulty was 
locating monomeric type I collagen molecules with both rBSP and anti-type I collagen 
antibody bound to it. In most instances, either unbound molecules (rBSP, anti-type I 
collagen antibodies and type I collagen) or singly bound proteins were observed.  
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Figure 3.3 Rotary-shadowing TEM of recombinant BSP. 
rBSP (50 µg/ml) was visualized by (B) rotary-shadowing with platinum at an angle of 5° 
and a single BSP molecule was selected for magnification (D). The buffer (70% 
glycerol/30% 0.01 M ammonium formate) was rotary-shadowed and served as the control 
(A). The schematic drawing [adapted from (9)] (C) illustrates the shape of rBSP particle 
found in (B, D) and in the literature (9). Scale bar = 100 nm 
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Figure 3.4 Rotary-shadowing TEM of type I collagen molecules.  
Type I collagen (prepared in-house and from Sigma) was dissolved in 70% glycerol/30% 
0.01M ammonium formate to a concentration of 5 µg/ml and rotary-shadowed. Both 
preparations of type I collagen have the characteristic semi-flexible, rod-like structure of 
monomeric type I collagen molecules (red rectangles). In addition, apparent type I 
collagen aggregates are observed with the in-house prepared collagen. The samples were 
analyzed in a Philips CM-10 TEM operating at 80 kV. Magnification 130,000 x. Scale 
bar = 100 nm 
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Figure 3.5 Rotary-shadowed N-terminal type I collagen antibodies with platinum. 
Rotary-shadowed antibodies to type I collagen (5µg/ml) possess a globular appearance 
with a diameter of approximately 10 nm. Representative anti-type I collagen antibodies 
are indicated by purple arrows. Magnification 130,000 x. Scale bar = 100 nm 
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Figure 3.6 Binding of rBSP on type I collagen.  
rBSP (50 µg/ml) and type I collagen (prepared in-house; 5 µg/ml) were incubated 
overnight at 4°C and rotary-shadowed with platinum (A). The binding location of rBSP 
on type I collagen is indicated by the white arrows. In addition, TEM studies were 
completed with the collagen obtained from Sigma and the binding of the N-terminal 
collagen antibody (black arrow) and rBSP are indicated (white arrow) (B). The binding 
location of rBSP on type I collagen is at a position of approximately 130 nm (white 
arrow) from the N-terminal end of the collagen molecule. Measurements were made 
using the ImageJ software. The total length of the individual collagen molecules and the 
distance of the rBSP binding site measured from N-terminal end of the collagen 
molecules are indicated. Magnification 130,000 x. Scale bar = 100 nm 
A 
B 
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3.4 DISCUSSION 
 The aim of the present study was to gain insight into the BSP-type I collagen 
interaction. We have previously determined that the BSP-type I collagen interaction is 
mainly hydrophobic in nature, but stabilized by electrostatic forces. Additionally, the type 
I collagen-binding region has been determined to be residues 18-45 on BSP, a highly 
conserved region that is rich in hydrophobic and basic amino acids (11). However, the 
BSP-binding region on type I collagen is unknown. In this study, using rotary-shadowing 
TEM, the BSP-binding site was localized on type I collagen.  
 Rotary-shadowing TEM shows rBSP as a monomer with a globular structure that 
is linked to an elongated thread-like structure, which is consistent with the findings of 
Wuttke et al. Moreover, Wuttke et al., proposed the globular structure of rBSP, expressed 
from human embryonic kidney (HEK 293) cells, to be the C-terminal region since it does 
not contain any glycans. In contrast, the thread-like structure contains the highly 
glycosylated structure located at residues 180-220 (9). However, with regards to the 
prokaryotically-expressed rBSP used in our studies, the globular structure is likely due to 
the high levels of hydrophobic residues, while the thread-like structure is likely due to the 
high content of acidic amino acids (12). 
 Both types of collagen used in this study were extracted from rat tail tendons 
which have been shown to be a good source of monomeric collagen. However, a small 
content of covalently cross-linked polymeric collagen is likely to be present as cross-
linking cannot be completely prevented or reversed (13). These cross-linked polymeric 
collagen molecules were observed with the in-house prepared collagen. With regards to 
the monomeric collagen molecules observed, the lengths of these molecules were 
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consistent with the findings of Dahl et al., which found the mean length to be 250 nm and 
standard deviation to be 48 (5). Unexpectedly, platinum-shadowed collagen molecules 
from Sigma were lighter in colour than the platinum-shadowed collagen molecules 
prepared in-house. This is likely due to a smaller amount of the contrast-enhancing metal 
(platinum) being evaporated onto the protein surface which is believed to have occurred 
during the processing of these samples in our studies (1-3).  
 The BSP-collagen interaction is only partly electrostatic and, in fact, it is mainly 
hydrophobic in nature (11). These findings parallel those of Kasugai et al., which 
determined that bone fragments demineralized with 4 M guanidine-HCl (a strong 
dissociative denaturant) still contained native BSP bound to type I collagen (14, 15). 
Therefore, it is postulated that BSP binds along the collagen molecule at a site with a 
surface chemistry that is, at least in part, hydrophobic. Type I collagen has an isoelectric 
point of 9.1 and a net charge of ~40+ at physiological pH. The molecule has a total of 
270 basic residues (Arg, Lys, Hyl, and His) and 222 acidic residues (Asp and Glu). 
However, there are three regions along the collagen molecule that contain areas of high 
hydrophobicity. Two of the regions are in an overlap zone (c2-c1, which corresponds to 
residues 213-248) and (a4-a3, residues 307-324), while one of the regions is in a gap 
region (a1-e2, residues 342-374). Of relevance, Maitland et al., proposed that the 
hydrophobic domains of NCPs are involved in binding to the hydrophobic domains of 
type I collagen (16).  Correlating these findings with the known triple-helical type I 
collagen sequences, the BSP-binding region (residues 255 to 372) comprises two regions 
along the collagen molecule that are high in hydrophobic amino acids, (a4-a3, a region 
encompassing residues 307-324) and (a1-e2, residues 342-374). 
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 Using a far-Western blotting technique, Fujisawa et al., found that BSP bound to 
the α2 chain of the collagen molecule. However, there are many potential issues with this 
study including the non-specific binding to the α1 chain and that the collagen utilized in 
this study was not in a triple-helical form (18). Previous work demonstrated that the 
triple-helical structure of type I collagen is important for interacting with BSP and it is 
likely that at least two of the α chains are involved (19).  San Antonio et al., mapped the 
binding sites of hundreds of type I collagen ligands onto a 2-D model of the fibril and the 
distribution of the binding sites suggest these can be organized into two domains: the 
“cell interaction domain” and the “matrix interaction domain”. The “cell interaction 
domain” comprising an overlap region contains integrin-mediated cell-to-cell 
interactions, while the “matrix interaction domain”, overlapping a gap region, contains 
ECM interactions.  
 We have previously demonstrated that two glutamic acid-rich regions are 
responsible for the nucleating activity, and this activity is increased 10-fold upon binding 
to collagen. Studies on calcified turkey tendon and in bone have shown initial mineral 
formation occurring in the gap regions of type I collagen (21-23). Moreover, Landis et 
al., proposed that the packing of consecutive 2-D collagen arrays into 3-D assemblages 
results in the formation of channels or gaps which are postulated to be the sites of 
nucleation. Furthermore, given the pore space between adjacent type I collagen 
molecules is 0.24 nm and the unstructured, flexible nature of BSP, it is postulated that the 
glutamic-acid regions can extend into the gap region of the adjacent collagen molecule 
and initiate mineral formation. Of relevance, DPP, a proposed mediator of mineralization 
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in dentin, has been shown to bind primarily to the fibril surface at the “e” band that is 
present in the middle of a gap region (24).  
 In conclusion, our findings suggest that the N-terminal hydrophobic sequence 
(residues 18-45) of BSP binds to collagen at a region that encompasses residues 258 to 
372. This corresponds to BSP binding an overlap region of the collagen fibril by its N-
terminal collagen-binding domain and the two glutamic acid rich regions binding in the 
gap region of the adjacent collagen molecule where it initiates mineral formation (Figure 
3.8) 
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Figure  3.7 Schematic of the triple-helical type I collagen sequences of the BSP 
binding site.  
The BSP-binding region on type I collagen is approximately 315±60 residues from the N-
terminal end of the collagen molecule, or residues 258 to 372. (A) Residues 255 to 342 
(purple rectangle) lie in an overlap region while (B) residues 343 to 372 (orange 
rectangle) lie in a gap region of the collagen fibril. The basic (Lys and Arg) and acidic 
residues (Asp and Glu) are shown in bold. Regions with a high concentration of charged 
residues are enclosed within rectangles and the letters correspond to the bands observed 
after positive staining of the collagen fibril. [Adapted from (17)] 
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Figure 3.8 Model of BSP-mediated hydroxyapatite nucleation.   
(A) BSP binds to type I collagen at a site that is approximately 31% from the N-terminal 
end of the molecule. (B) This corresponds to BSP binding an overlap region of the 
collagen fibril by its N-terminal collagen-binding domain (purple) and the two glutamic 
acid rich regions (brown) binding in the gap region of the adjacent collagen molecule 
where it initiates mineral formation.   
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4.1 INTRODUCTION  
 The extracellular matrix (ECM) is a dynamic structure that constantly undergoes 
changes in response to stimuli such as inflammation, wound healing and cancer (1). 
There are many proteinases that mediate the degradation of the ECM including the matrix 
metalloproteinase (MMP) family, the adamalysin-related membrane proteinases 
(ADAMs) family and tissue serine proteinases such as thrombin (2).  
 Thrombin is a multifunctional protease that is important in a number of biological 
processes such as blood coagulation and bone formation. The precursor of thrombin, 
prothrombin, (also known as Factor II), is produced in the liver and secreted into the 
blood circulation. Upon injury, prothrombin is converted to thrombin by the 
prothrombinase complex for blood clot formation (3). The involvement of thrombin in 
bone repair is primarily via the activation of protease-activated receptor 1 (PAR-1), a G 
protein-coupled receptor expressed by osteoblasts, thereby mediating proliferation of 
these cells (4). Thrombin also inhibits apoptosis of osteoblasts (5). In addition, thrombin 
cleaves a number of ECM proteins such as osteopontin (OPN) (6) and bone sialoprotein 
(BSP) (7).  
 Previous studies from our laboratory have shown that thrombin cleaves rat BSP at 
Arg27-Tyr28, a site that is conserved in mouse, pig and human, but not in cow, which has 
a thrombin-cleavage site at Arg122-Lys123 (7). Interestingly, thrombin cleaves rat BSP 
in the middle of the collagen-binding domain (BSP18-45), which effectively abolishes 
collagen-binding (unpublished data). The physiological relevance of this conserved 
thrombin cleavage site, however, has not been fully elucidated and is the main focus of 
this study.   
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 In addition to hydroxyapatite (HA) nucleation, acidic phosphoproteins of the 
ECM also function as signaling molecules in physiological pathways (8, 9). BSP contains 
a highly-conserved C-terminal RGD sequence that interacts with the αvβ3 integrin and has 
been shown to be important in cell adhesion and migration of osteoblast and tumor cells 
(8-12). In addition, BSP has been shown to promote angiogenesis by facilitating the 
migration and attachment of human umbilical vein endothelial cells (13). 
 Since BSP has been shown to be a chemotactic agent, we hypothesize that, upon 
bone injury, thrombin becomes activated, then cleaves and releases BSP into the ECM. 
Subsequently, BSP can act as a signal molecule to recruit osteoprogenitor cells that will 
differentiate into osteoblasts. The purpose of this study was to determine whether 
thrombin cleaves and releases BSP from type I collagen. Thrombin-digestion reactions 
were completed and analyzed using SDS-PAGE and staining with Stains-All and silver, 
Western blotting and MALDI-MS.  
4.2 MATERIALS AND METHODS 
4.2.1  MATERIALS  
 Human alpha-thrombin was purchased from Haematologic Technologies Inc. 
(Essex Junction, VT). Type I collagen was extracted from rat tail tendons in our 
laboratory as previously described (14). Sprague-Dawley rats (250-300 g) were obtained 
from Charles River Breeding Laboratories (Wilmington, MA). Amino-caproic acid, 
benzamidine HCl, N-ethyl maleimide and phenylmethylsulfonyl fluoride (PMSF) and N-
Tris(hydroxymethyl)methyl-2 aminoethanesulfonic acid (TES) were all purchased from 
Sigma-Aldrich (St. Louis, MO). 
 For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
ammonium persulfate (APS), N, N, N’, N’-tetramethylethane-1,2-diamine (TEMED), 
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acrylamide/bis-acryalmide, SDS and pre-stained protein standards were purchased from 
Bio-Rad Laboratories (Hercules, CA). β-mercaptoethanol and glycine were obtained 
from Thermo Fisher Scientific (Rockford, IL). Isopropanol was from VWR International 
(West Chester, PA). Imidazole, Stains-All and silver nitrate were purchased from Sigma-
Aldrich. Anti-BSP was purchased from abcam
® 
(Toronto, Ontario). Hybond-P 
polyvinylidene fluoride transfer (PVDF) membranes, enhanced chemiluminescence 
(ECL) reagents, hyperfilm-ECL film and horseradish peroxidase (HRP)-conjugated anti-
rabbit antibodies were obtained from GE Healthcare (Amersham).  
4.2.2 METHODS 
4.2.2.1 Thrombin cleavage of recombinant BSP (rBSP) bound to type I collagen 
 An overview of the thrombin-digestion experiments on rBSP bound to type I 
collagen is illustrated in Figure 4.1. rBSP (10 µg) was incubated with either (1) type I 
collagen fibrils or (2) soluble type I collagen that was subsequently allowed to form 
fibrils. The two set-ups are described below.  
a) Incubation of rBSP after collagen fibril formation  
 Type I collagen (4 mg/ml) fibril formation was induced with the addition of 250 
µl TES-phosphate buffer (270 mM NaCl, 30 mM Na2HPO4 and 60 mM TES pH 7.5) at 
37°C and incubated for 4 h. Subsequently, rBSP (10 µg) was added to the collagen fibrils 
and incubated overnight at 4°C. This should result in rBSP binding to the surface of the 
collagen fibrils. 
b) Incubation of rBSP before collagen fibril formation  
  rBSP (10 µg) was incubated with soluble type I collagen (4 mg/ml) overnight at 
4°C. Subsequently, fibril formation was induced with the addition of TES-phosphate 
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buffer at 37°C for 4 h. This should result in some of the rBSP being internalized within 
the collagen fibrils. 
 In both set-ups (a and b), unbound rBSP was first removed by buffer exchange 
using Amicon® Ultra-0.5 centrifugal filter units. A total of five buffer exchanges were 
performed. The BSP-collagen complexes were then incubated with thrombin (0.08 U) in 
digestion buffer (50 mM Tris HCl, 10 mM CaCl2, and 1X PBS) at 22°C for 2 h.  After 
recovery of supernatant, the two different preparations of rBSP and type I collagen were 
then incubated with 10% SDS at 22°C for 1 h to release any rBSP that was still 
associated with the collagen fibrils. The recovered solutions were analyzed by 12% SDS-
PAGE gel and staining with Stains-All and silver as previously described (15) or loaded 
onto a 6% SDS-PAGE gel and transferred onto a PVDF for western blot analysis. Briefly, 
membranes were blocked with 5% milk powder in phosphate-buffered saline containing 
Tween-20 (PBS-T) and incubated overnight at 4°C. The membranes were then incubated 
with anti-BSP (1:500 dilution) for 1 h followed by incubation with anti-rabbit-HRP 
antibodies (1:1000 dilution, GE Healthcare) for another hour. Four consecutive washes 
(10 min) with PBS-T were completed between incubation steps. The membranes were 
then developed with ECL reagents (5 min) and analyzed using the ChemiImager 5500 gel 
doc system and corresponding software (Alpha Innotech).  
4.2.2.2 Thrombin cleavage of native BSP (nBSP) and demineralized rat bone 
fragments  
 Rat bone nBSP was extracted as previously described (16). nBSP (5 µg) was 
incubated with thrombin (0.08 U) in thrombin-digestion buffer at 22°C for 2 h. The 
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reaction solutions were then concentrated and loaded onto a 12% SDS-PAGE gel and 
stained with Stains-All and silver for analysis (15).  
 To prepare demineralized bone chips for study of thrombin susceptibility, an 
established bone extraction protocol was followed (16). Briefly, adult rat tibia, femur, 
humerus, radius and ulna were excised and fragmented into large chunks with a hammer 
and chisel. Subsequently, the bone fragments were further broken down with a mortar 
and pestle under liquid nitrogen. The bone chips were then freeze-thawed with 1X PBS 
containing proteinases inhibitor (PI; 100 mM amino-caproic acid, 5 mM benzamidine 
HCl, 5 mM N-ethyl maleimide and 1 mM PMSF). This was repeated for a total of four 
times. Bone chips were then incubated with chloroform: methanol (3:1) at 4°C for 2 h to 
remove adipose tissue. 1X PBS (containing PI) was then used to remove the chloroform: 
methanol. Subsequently, noncollagenous proteins were extracted from the chips using 4 
M GuHCl/50 mM Tris buffer, pH 7.4, containing PI (1l a day per 100 g bone) for four 
days. A 24-h wash with 1X PBS (exchanged three times) was then used to remove the 4 
M GuHCl/Tris buffer. Following this, mineral-associated proteins were extracted using 
0.5 M EDTA/ 50 mM Tris buffer, pH 7.4, containing PI (50 ml of EDTA solution per 
gram of bone per day) for four days. After the removal of the EDTA extract solutions, 
bone fragments were washed with 1X PBS for a total of three times.  
 The bone fragments (known to contain BSP bound to type I collagen) (17, 18) 
were then incubated with various concentrations of thrombin (0.02 – 0.08 U) in 
thrombin-digestion buffer at 22°C for 2 h. The reaction solutions were concentrated to 40 
µl and loaded onto a 6% SDS-PAGE gel and transferred onto a PVDF membrane for 
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western blot analysis as described earlier or loaded onto a 12% SDS-PAGE gel and 
stained with Stains-All and silver (15).   
4.2.2.3 Matrix-assisted laser desorption mass spectrometry (MALDI-MS) analysis 
 The collagenous residue of the demineralized rat bone fragments (after incubation 
with thrombin) and non-digested nBSP were analyzed by MALDI-MS (Bruker® Reflex 
IV, MALDI TOF MS, Department of Biochemistry, UWO). Sample aliquots of 2 µl were 
mixed with 2 µl of sinapinic acid in 50 % methanol/0.5% trifluroacetic acid and spotted 
onto a 96-well MALDI plate. The plate was analyzed using a Reflex IV MALDI-TOF 
instrument in positive-ion mode. Mass spectra were collected and peaks were assigned 
using the XTOF software (Bruker, Germany). 
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Figure 4.1 An overview of the thrombin digestion experiments of rBSP bound to 
type I collagen. rBSP (10 µg) was incubated with either type I collagen fibrils (left) or 
soluble type I collagen (right) that was subsequently allowed to form fibrils. Prior to the 
addition and incubation of thrombin, unbound rBSP was removed by buffer exchange. 
The thrombin-digestion products were analyzed by Stains-All and silver.  
 
 
 
 
Incubation of rBSP after 
collagen fibril formation 
Incubation of rBSP before 
collagen fibril formation 
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4.3 RESULTS 
4.3.1 Thrombin cleavage of rBSP bound to type I collagen  
 The two different preparations of rBSP and type I collagen were incubated with 
thrombin and the products were analyzed by Stains-All and silver staining and western 
blot. To ensure that the rBSP detected was the result of thrombin cleavage and not 
unbound rBSP, multiple washes were done using 1X PBS (prior to the incubation with 
thrombin). The first and fifth washes were also loaded onto the gels (Figures 4.2A and 
4.2B, W1 and W5).  
 A band of approximately 55 kDa is apparent in the first washes and after addition 
and incubation with thrombin (Figures 4.2A and 4.2B, W1 and +thrombin lanes) from 
both rBSP-collagen preparations. However, the intensity of the band in the +thrombin 
lanes at 55 kDa from the rBSP incubated with fibrillar collagen is stronger than the 
corresponding band recovered from the preparation of rBSP preincubated with 
monomeric collagen prior to reconstitution (Figure 4.2A[a]). Following incubation with 
thrombin, both rBSP-collagen preparations were incubated with 10% SDS to recover all 
non-covalently bound protein. A band of approximately 55 kDa is apparent (Figure 4.2A, 
+SDS lanes). This suggests that the rBSP detected after incubation with thrombin was 
released from the surface of the (a) collagen fibrils or (b) within the collagen fibrils. 
However, the intensity of the bands in (Figure 4.2B, rBSP only and + thrombin lanes) are 
not expected based on the intensity of the bands in (Figure 4.2A, rBSP only and + 
thrombin lanes), a possible explanation for this is that  full-length rBSP reacts poorly 
with anti-BSP.    
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4.3.2 Analysis of nBSP and demineralized rat bone fragments for 
thrombin susceptibility  
 
 nBSP was analyzed for thrombin susceptibility. Non-digested nBSP has an 
apparent Mr of 80 kDa, whereas after incubation with thrombin a second band at 
approximately 60 kDa is apparent (Figure 4.3A, +thrombin). 
 Rat bone fragments that were first demineralized were also analyzed for thrombin 
susceptibility and release of BSP. The collagenous residue after EDTA was incubated 
with various concentrations of thrombin (0.02 – 0.08 U) in thrombin-digestion buffer at 
22°C for 2 h and the products were analyzed by SDS-PAGE and stained with Stains-All 
and silver and western blotting. From the western blot analysis, solutions recovered from 
incubated bone chips without thrombin contained BSP-immunoreactive bands with 
apparent molecular weights of 180, 80 and 60 kDa (Figure 4.3C, -thrombin lane). 
Addition of increasing amounts of thrombin resulted in a corresponding increased 
recovery of bands at 180, 80 and 60 kDa and evidence of lower-molecular-weight 
peptides (Figure 4.3C, +thrombin lanes).  It is believed that the slower-migrating protein 
(180 kDa) represents polymers of BSP. Stains-All and silver staining of the recovered 
proteins after thrombin incubation shows a mixture of proteins with a prominent band at 
approximately 60 kDa (Figure 4.3B, +thrombin lane).  
4.3.3 Matrix-assisted laser desorption mass spectrometry (MALDI-MS) 
analysis  
 
 The thrombin-digested reactions of the demineralized rat bone fragments and 
controls containing no thrombin were analyzed by MALDI-MS.  The non-digested rat 
native BSP (control) gave rise to a peak at 52,423 m/z (Figure 4.4A) whereas the 
thrombin-digested rat native BSP gave rise to a peak at approximately 47,500 m/z 
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resulting in a loss of approximately 5000 m/z. Thrombin gave rise to a peak at 36,708 
m/z. MALDI-MS analysis of the thrombin-digested demineralized bone fragments 
reveals a major peak at 43,784 m/z and minor peaks at 34,112 m/z, 28,069 m/z, 22,025 
m/z and 13,727 m/z (Figure 4.4D). This is not consistent with the western blot analysis 
(Figure 4.3A), suggesting that non-BSP proteins in the sample were identified by MS.  
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Figure 4.2 Analysis of thrombin-digestion reactions of rBSP bound to type I 
collagen. 
Prior to the addition and incubation with thrombin, unbound rBSP from the two different 
rBSP-collagen preparations - (a) rBSP on the surface of collagen fibrils and (b) some 
rBSP internalized within the collagen fibrils - was removed with a total of five buffer 
exchanges using 1X PBS. Following this, (a) and (b) were incubated with 10% SDS. The 
products (the first and fifth washes, incubation with thrombin and 10% SDS) were 
collected and loaded onto a (A) 12% SDS-PAGE gel and stained with Stains-All and 
silver for analysis or (B) loaded onto a 6% SDS-PAGE gel and transferred onto a PVDF 
membrane and incubated with anti-BSP antibodies to probe for BSP. A band 
corresponding to the release of rBSP from type I collagen fibrils is apparent at 55 kDa 
[W1, +thrombin and +SDS lanes in (a) and (b)]. “M” is the molecular marker.  
 
A 
B 
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Figure 4.3 Analysis of nBSP and demineralized rat bone fragments for thrombin 
susceptibility.  
nBSP was incubated with thrombin and the reactions were concentrated and loaded onto 
a (A) 12% SDS-PAGE gel and stained with Stains-All and silver for analysis. 
Additionally, rat bone fragments that were first demineralized with EDTA was incubated 
with various concentrations of thrombin in digestion buffer at 22°C for 2 h. The reactions 
were loaded onto a (B) 12% SDS-PAGE gel and stained with Stains-all and silver for 
analysis or loaded onto a (C) 6% SDS-PAGE gel and transferred onto a PVDF membrane 
and incubated with anti-BSP antibodies to probe for BSP. Bands corresponding to the 
release of nBSP (C; red box) were present when incubated at all concentrations of 
thrombin. “M” is the molecular marker. 
A B 
C 
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Figure 4.4 MS analysis of thrombin-digested demineralized bone chips  
(A) Mass spectrum of non-digested rat BSP with a dominant peak at 52,423 m/z. 
(B) Mass spectrum of thrombin-digested rat BSP with a dominant peak at approximately 
47,500 m/z.  
(C) Mass spectrum of thrombin with a dominant peak at 36,708 m/z. 
(D) Mass spectrum of thrombin-digested rat bone showing a dominant peak at 43,784 
m/z and minor peaks at 34,112 m/z, 28,069 m/z, 22,025 m/z and 13,727 m/z. 
A B 
C D 
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4.4 DISCUSSION   
 Bone formation and remodeling are complex, yet still poorly understood, 
processes that involve many factors. The acidic phosphoproteins of the ECM have been 
shown to function as signaling molecules in physiological pathways. The aim of the 
present study was to gain insight into the conserved thrombin-cleavage site of BSP. 
Previous studies from our laboratory have shown that thrombin cleaves rat BSP at Arg27-
Tyr28. In this study, we present evidence that rBSP bound to type I collagen and 
demineralized rat bone fragments (containing nBSP bound to type I collagen) are 
susceptible to thrombin cleavage. This was confirmed with Stains-All and silver, western 
blot and MALDI-MS analysis. 
 nBSP was analyzed for thrombin susceptibility. A 60-kDa band was apparent 
after incubation with thrombin. This was not expected based on the thrombin-cleavage 
site at Arg27-Tyr28. Previous unpublished data from our laboratory show non-digested 
rBSP with a peak at ~34,754 (m/z), while the thrombin-digested rBSP had a peak at 
~30,761 (m/z), resulting in a loss of approximately 4,000 m/z. Therefore, the expected 
BSP fragment would be approximately 4 kDa less than the full-length and this loss may 
not be evident on SDS-PAGE. This shortened BSP fragment at 60 kDa was also evident 
in the western blot analysis of demineralized rat bone fragments which is likely due to the 
slow migration of BSP. Moreover, the additional bands below 60 kDa are possibly 
proteolytic fragments of BSP while the high-molecular-weight bands may be a result of 
transglutaminase, a protein-crosslinking enzyme that generates polymers of BSP (19). 
This observation of a shortened BSP fragment at 60 kDa is consistent with the findings of 
Gorski et al., where proteolytic fragments of BSP (45-50 kDa) were found in bone 
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mineralization foci (BMF). Moreover, in the presence of a serine protease inhibitor 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), cleavage of BSP was 
inhibited. This suggests the BSP fragments were a result of serine protease activity, 
which thrombin is a serine protease (20).   
 The MS peak at 52,423 m/z for the non-digested BSP (control) coincides with the 
findings of Zaia et al. (21) and Wuttke et al. (22). However, the dominant MS peak at 
43,784  m/z for thrombin-digested bone was not expected based on the thrombin-
cleavage site at Arg27-Tyr28. The expected peak for the demineralized rat bone 
fragments (after incubation with thrombin) would be closer to 47,500 m/z based on the 
thrombin-digested BSP. Since the Stains-All and silver staining of the demineralized rat 
bone fragments showed a mixture of proteins, this suggests the unexpected MS peak is 
not likely BSP. Although MS has been demonstrated to be a good tool in proteomic 
analysis, the highly acidic nature of BSP appears to be a problem for detection by MS. 
Previous studies from our laboratory have shown that a chondroitin sulfate proteoglycan, 
with a highly acidic protein core, was not detectable by MS (unpublished data). A 
potential explanation for this is that the less-negatively charged proteins in the sample 
mixture are more easily protonated and detected by MS than BSP.  
 For proteins to become functional, often proteolysis is required. Also, processing 
of protein through proteolysis could potentially modulate its functional roles. Many 
polypeptides isolated from bone and dentin have been shown to be distinct proteolytic-
derived large peptides. In some instances, it has been demonstrated that these cleavages 
are necessary for protein function. Dentin sialophosphoprotein (DSPP) the inactive 
precursor, is cleaved by PHEX, resulting in two active fragments, dentin sialoprotein 
109 
 
(DSP) and dentin phosphophoryn (DPP) (23). Similarly, dentin matrix protein 1 (DMP-1) 
exists as 37-kDa and 57-kDa peptides and it has been proposed that this cleavage is 
important in osteogenesis and dentinogenesis (24). Of relevance, thrombin also cleaves 
OPN at a Gly-Arg-Gly-Asp-Ser (GRGDS) site into an N-terminal and a C-terminal 
fragment. Many studies have analyzed the physiological relevance of this cleavage. 
Grassinger et al., demonstrated that the N-terminal thrombin-cleaved OPN fragment acts 
as a chemotactic agent for hemopoietic stem and progenitor cells via α9β1 and α4β1 
integrins (25). Similarly, thrombin-cleaved OPN fragments have been shown to induce 
migration of a variety of cell types including monocytes, macrophages, neutrophils and 
lymphocytes (26-29).  
 There are several physiological processes that require the migration of 
osteoprogenitor cells. During the normal processes of bone remodeling and bone repair, 
there is a recruitment of osteoprogenitor cells responsible for generating mature bone. 
Although there are numerous factors within bone that can stimulate cell migration such as 
cytokines, the restricted expression of BSP to cells of osteogenic origin suggests BSP 
may act as an ECM signal. Moreover, BSP has been shown to act as a chemotactic agent 
for osteoblast and cancer cells through the activation of the focal adhesion kinase (FAK) 
and extracellular signal-regulated kinase (ERK) signaling pathway (8-12, 30). FAK is a 
tyrosine kinase that is activated when it is phosphorylated at Tyr397 (31). Following, FAK 
associates with various SH2/SH3 domain-containing proteins including Src and Grb2 
(32). This results in the activation of the mitogen-activated protein kinase (MAPK) 
pathway, such as ERK via the GTPase such as Ras (33). ERK has been demonstrated to 
be important in cell migration through the activation of downstream targets such as 
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members of the activator protein-1 (AP-1) (34). BSP has been demonstrated to influence 
osteoblast differentiation (10) through the activation of osteoblast-related transcription 
factors including Runx2 (35), alkaline phosphatase and Osx (36).   
 In the present study, we demonstrated that BSP bound to type I collagen is 
susceptible to thrombin cleavage.  We speculate that BSP released from bone by 
thrombin may function as a chemotactic agent in bone repair. In order to evaluate this 
hypothesis, we will have to determine whether intact and/or degraded BSP is released 
from the mineralized collagenous matrix after injury and whether thrombin-cleaved BSP 
from collagen can mediate osteoblast differentiation. The results from these studies will 
provide further insight into the physiological significance of this cleavage.  
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5.1 SUMMARY 
 Biomineralization is a complex, yet poorly understood, process that involves 
many factors. The precise mechanisms of crystal nucleation and growth are unknown. 
The highly organized arrangement of hydroxyapatite (HA) within the collagen matrix 
suggests that mineralization in bone is a tightly regulated process. Furthermore, 
dysregulation results in pathological conditions such as osteogenesis imperfecta. In 
normal calcified bone, the HA crystals tend to be plate-like (with average dimensions of 
~45 nm in length, ~25 nm in width and 3-6 nm thick) and are aligned parallel to one 
another and with their long axes parallel to the collagen fibrils (1, 2). In contrast, the HA 
crystals in pathologically calcified tissues, may be thick, bulky blocks or narrow spear-
shaped structures with dimensions that are three-to ten-fold larger than normal HA 
crystals (3), or may be similar in shape (plate-like) to normal crystals, but thinner (4). 
Additionally, the abnormal HA crystals are not aligned with respect to the long axis of 
the collagen fibrils (3, 4). Irregularities in the collagen matrix, where the overlap and gap 
regions are mismatched, is proposed to be responsible for the various sizes and shapes of 
HA crystals found in pathological calcified tissues. 
 While there are several postulated mechanism for biomineralization, one 
prominent mechanism requires preexistence of a surface such as type I collagen for ion 
deposition and nucleation by acidic proteins (5-7). The collagen matrix neither promotes 
nor inhibits HA nucleation, however; an acidic phosphoprotein of the ECM is proposed 
to be play this role. Bone sialoprotein (BSP) is a likely candidate due to its spatio-
temporal pattern of expression and HA-nucleating capabilities (8-10). Moreover, since 
this nucleation activity is increased upon binding to collagen, it is postulated that BSP is 
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secreted into the ECM by osteoblasts, binds to type I collagen in the gap regions (where 
initial mineral formation is seen to occur), or the regions adjacent to it, and mediates 
mineral formation. 
 Previous work demonstrated that the BSP-collagen interaction is mainly 
hydrophobic in nature, but stabilized by electrostatic forces. The collagen-binding region 
has been located to a region spanning residues 18-45 on BSP, a highly conserved region 
that is rich in hydrophobic and basic amino acids (11). The BSP-collagen interaction 
requires a native triple-helical type I collagen structure, but does not require either 
collagen telopeptides or fibrils (12). Furthermore, post-translational modifications 
(PTMs) are not involved in collagen-binding since both rat-bone-extracted BSP and 
recombinant BSP (rBSP; unmodified BSP) demonstrate comparable binding affinities. 
Although much research has been devoted to studying the BSP-collagen interaction, the 
BSP-binding region on type I collagen has not been identified and was the main focus of 
this thesis.  
  In chapter two, a chemical cross-linking method was initially used to determine 
the BSP-interacting domain on type I collagen. These experiments involved the 
incubation and conjugation of single-cysteine rBSP (1-100) mutants to the sulfhydryl 
reactive, photoactivable cross-linkers APB and APDP. Type I collagen was then added 
and irradiated with UV light to induce cross-link formation. Multiple approaches and 
modifications were taken in an effort to improve the efficiency and/or recovery of BSP-
collagen cross-linked products. However, the yield of the cross-linked products was low 
in all instances and therefore the complexes were not further characterized. It is still a 
puzzle as to why the chemical cross-linkers did not result in sufficient cross-linked 
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products, as both cross-linkers have been used successfully in many cross-linking 
experiments studying protein-protein interactions. A possible explanation lies in the 
cross-linkers’ spacer arms; perhaps these were not long enough to reach a collagen amino 
acid from the cysteine residue of the single-cysteine rBSP (1-100) peptide. Unfortunately, 
these two cross-linkers possess the longest spacer arms among commercially available 
heterobifunctional cysteine-reactive cross-linkers with a photoactivable group. Another 
potential explanation is that the current method of detection was not sufficiently sensitive 
to detect the BSP-collagen cross-linked products. Therefore, due to these difficulties in 
obtaining sufficient BSP-collagen cross-linked products, an alternative protocol using 
rotary-shadowing TEM was used. 
 Rotary-shadowing TEM has been utilized extensively for identifying the binding 
site(s) of various proteins on collagen as it offers high-contrast visualization of individual 
macromolecules. In chapter three, this method was used to visualize the BSP-interacting 
domain on collagen. This involved rotary-shadowing with platinum full-length 
prokaryotically expressed rBSP, type I collagen (extracted from rat tail tendons) and an 
anti-type I collagen antibody recognizing the N-terminal end of collagen molecules. 
Rotary-shadowing TEM shows rBSP as a monomer possessing a globular structure of 
~10 nm linked to an elongated thread-like structure of ~25 nm, while type I collagen 
appeared as semi-flexible molecules. These structures are consistent with the findings in 
the literature (13, 14). The locus of interaction is approximately 31% from the N-terminus 
based on studies in which BSP, type I collagen and an antibody recognizing the N-
terminal end of the collagen molecule were combined. Taking this into consideration, as 
well as the arrangement of the collagen fibril, the highly flexible structure of BSP and the 
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hydrophobic nature of the BSP-collagen interaction, I postulate that the N-terminal 
hydrophobic sequence (residues 18-45) of BSP binds collagen in an overlap region at a 
site that is rich in hydrophobic residues, while one or both of the glutamic acid-rich 
regions extend into the gap region of the adjacent collagen molecule.  
  In addition to HA nucleation, BSP has been demonstrated to function as a 
signaling molecule. BSP contains a highly conserved C-terminal RGD site that interacts 
with the αvβ3 integrin and has been shown to be important in osteoprogenitor cell 
migration and differentiation (15-17). Within the collagen-binding domain of BSP, there 
is a highly conserved thrombin cleavage site at Arg27-Tyr28. Thrombin cleaves rat BSP 
in the middle of the collagen-binding domain (residues 18-45), which effectively 
abolishes collagen binding, implying physiological significance. To address the relevance 
of this, analysis of the products of the incubation of thrombin with rBSP bound to fibrillar 
collagen and with demineralized bone chips was completed. Analysis with SDS-PAGE 
and western blotting demonstrated that rBSP bound to type I collagen fibrils is 
susceptible to thrombin cleavage allowing for its release from the collagen complex. 
Similarly, endogenous BSP present in demineralized bone chips is also released from 
these chips with thrombin incubation. Since BSP has been shown to function as a 
chemotactic agent, I hypothesize that, upon bone injury, thrombin becomes activated, 
cleaves and releases BSP into the ECM. Subsequently, BSP can act as a signal molecule 
to recruit osteoprogenitor cells which will differentiate into osteoblasts. 
Conclusions and Future Directions   
 The first objective of this thesis was to ultimately map the BSP-binding region on 
type I collagen down to the amino-acid level. As the present studies provide qualitative 
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insight into the BSP-binding domain on collagen, future studies will be important to fully 
elucidate this domain and to determine how this interaction promotes nucleation of HA. 
Future TEM studies to validate the BSP-binding domain on collagen could involve the 
use of the biotinylated rBSP (18-45) peptide present in the laboratory. This approach is 
promising since a shorter peptide than the rBSP (1-100) peptide may reduce the inherent 
variability noted in the site of interaction with the larger peptide.  Furthermore, because 
of the strong binding affinity of avidin to biotin and the relatively large mass of avidin, 
the site of interaction should be readily apparent. In addition, synthetic triple-helical type 
I collagen peptides can be synthesized and utilized in solid-binding assays to further 
characterize the BSP-binding region. Researchers have extensively used synthetic triple-
helical peptides of type II and III collagen to map protein- or peptide-binding locations 
(18). Moreover, the BSP-binding site on collagen determined in this present study can be 
used as constraints in molecular-modeling techniques to generate a predicted structure 
(19, 20). Additionally, structural studies such as 
1
H NMR, CD and X-ray scattering may 
be used to determine change in BSP conformation, if any, upon binding to collagen (21).  
 The findings of the second objective suggest that the release of BSP from bone 
may provide signals to initiate the bone repair process. In order to evaluate this 
hypothesis, it is important to determine whether full-length and/or degraded BSP is 
released from the mineralized collagenous matrix after injury and whether thrombin-
cleaved BSP from collagen can mediate osteoblast differentiation. Although MS has been 
demonstrated to be a good tool in proteomic analysis, the highly acidic nature of BSP 
may pose a problem. In the present study, the thrombin-digested BSP in the 
demineralized bone mixtrue was not detectable by MS. A potential explanation is that in 
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a mixture of proteins, the less-acidic proteins are more easily protonated and detected by 
MS. Thus, additional purification and concentration of the acidic peptides prior to 
analysis by MS should be included, similar to what was done for the analysis of the 
highly phosphorylated osteopontin (22).The results from these studies will provide 
further insight into the physiological significance of this cleavage.  
  In cases where the injury is so severe that natural healing cannot take place, the 
use of biomaterials may aid the healing process. These materials can be classified into 
three groups (1) osteoinductive, (2) osteoconductive, and (3) calcigenic materials (23). 
Established osteoinductive materials, such as BMP, are involved in the recruitment and 
differentiation of osteoprogenitor cells into osteoblasts (24).  However, disadvantages of 
BMP are the cost and the potential for serious side effects. While BSP has apparent 
osteoinductive properties in vitro, studies in vivo are not yet conclusive.  
Osteoconductive materials such as HA composites provide a scaffold upon which bone 
can form. However, these materials can result in disorganized mineralization of bone 
tissues (24). Finally, calcigenic materials are involved in inducing local calcification 
rather than bone formation, which would allow the bone defect itself to be stabilized and 
potentially repaired more rapidly. This involves a calcigenic agent binding to a collagen 
scaffold in order to produce a mineralized matrix that is biologically and structurally 
comparable to bone (25). A postulated calcigenic agent is BSP.  
 In conclusion, the findings from these studies have added novel information to the 
BSP-collagen interaction and its role in bone formation and mineralization. This may 
ultimately lead to the generation of therapeutic agents to promote bone repair. 
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